Abstract
Radiopharmaceutical sciences summarizes all scientific aspects comprising chemistry, physics, and biology/pharmacology that deal with incorporating a suitable radionuclide into a pharmaceutical or other biologically active molecule or molecular entity. The resulting radiopharmaceuticals are used in nuclear medicine applications both for diagnosis [meaning noninvasive scintigraphic imaging] and for internal radiotherapy [1]. Internal radiotherapy is nowadays called radioligand therapy (RLT) or endoradiotherapy and altogether, i.e., noninvasive scintigraphic imaging and therapy, is summarized under the term radiothera(g)nostics.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsNotes
- 1.
Nuclear reaction cross section: 1 barn (b) = 10−28 m2.
- 2.
Transient equilibrium: Physical half-life of parent radionuclide T1 is longer than daughter T2 (T1 > T2).
- 3.
Secular equilibrium: Physical half-life of parent radionuclide T1 is much longer than daughter T2 (T1 ≫ T2).
References
Stöcklin G, Qaim SM, Rösch F. The impact of radioactivity on medicine. Radiochim Acta. 1995;70-1:249–72.
Qaim SM. Nuclear data for production and medical application of radionuclides: present status and future needs. Nucl Med Biol. 2017;44:31–49.
Ametamey SM, Honer M, Schubiger PA. Molecular imaging with PET. Chem Rev. 2008;108:1501–16.
Krasikova R. PET radiochemistry automation: state of the art and future trends in 18F-nucleophilic fluorination. Curr Org Chem. 2013;17:2097–107.
Honer M, Gobbi L, Martarello L, Comley RA. Radioligand development for molecular imaging of the central nervous system with positron emission tomography. Drug Discov Today. 2014;19:1936–44.
Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD. Consensus nomenclature rules for radiopharmaceutical chemistry – setting the record straight. Nucl Med Biol. 2017;55:v–xi.
de Goeij JJM, Bonardi ML. How do we define the concepts specific activity, radioactive concentration, carrier, carrier-free and no-carrier-added? J Radioanal Nucl Chem. 2005;263:13–8.
Ermert J. Labelling with positron emitters of pnicogens and chalcogens. J Label Compd Radiopharm. 2018;61:179–95.
Piel M, Vernaleken I, Rösch F. Positron emission tomography in CNS drug discovery and drug monitoring. J Med Chem. 2014;57:9232–58.
Brust P, van den Hoff J, Steinbach J. Development of 18F-labeled radiotracers for neuroreceptor imaging with positron emission tomography. Neurosci Bull. 2014;30:777–811.
Haberkorn U, Mier W, Kopka K, Herold-Mende C, Altmann A, Babich J. Identification of ligands and translation to clinical applications. J Nucl Med. 2017;58:27S–33S.
Martić-Kehl MI, Schibli R, Schubiger PA. Can animal data predict human outcome? Problems and pitfalls of translational animal research. Eur J Nucl Med Mol Imaging. 2012;39:1492–6.
Rutherford E. LIV. Collision of α particles with light atoms. IV. An anomalous effect in nitrogen. J Sci. 1919;37:581–7.
Curie I, Joliot F. Un nouveau type de radioactivité. Comptes Rendus. 1934;198:254–6.
IAEA. Research reactors: purposes and future. Technical reports series no. 470. Vienna: International Atomic Energy Agency; 2016.
Goethals P, Zimmermann R. A report on cyclotron used in nuclear medicine: world market report & directory. Ottignies-Louvain-la-Neuve: MEDraysintell; 2015.
Habs D, Köster U. Production of medical radioisotopes with high specific activity in photonuclear reactions with γ-beams of high intensity and large brilliance. Appl Phys B. 2011;103:501–19.
Failla G (1923) System for radium emanation. Patent
Stang LGJ, Tucker WD, Doering RF, Weiss AJ, Greene MW, Banks HOJ (1957) Development of methods for the production of certain short-lived radionuclides. In: Proceedings of the First UNESCO conference, 1957, Paris
Dash A, Chakravarty R. Pivotal role of separation chemistry in the development of radionuclide enerators to meet clinical demands. RCS Adv. 2014;4:42779–803.
Hendee WR, Bednarek DR. The concepts of transient and secular equilibrium are incorrectly described in most textbooks, and incorrectly taught to most physics students and residents. Med Phys. 2004;31:1313–5.
Rösch F, Knapp FFR. Radionuclide generators. In: Vertes A, et al., editors. Handbook of nuclear chemistry. Dordrecht: Springer; 2011.
Leichner PK. Radiation dosimetry of monoclonal antibodies: practical considerations. In: Henkin RE, et al., editors. Nuclear medicine. St. Louis, MO: Mosby; 1996. p. 558–62.
Yang S, Kim K, Zaman M, Naik H, Kim G, Song T-Y, Lee Y-O, Shin SG, Key Y-U, Cho M-H. Isomeric yield ratios for the natNd(γ, xn)1391m,g;141m,gNd reactions in the bremsstrahlung energy region from 45 to 60 MeV. J Radioanal Nucl Chem. 2014;300:367–77.
IAEA. Handbook on photonuclear data for applications cross-sections and spectra final report of a co-ordinated research project 1996–1999. IAEA TECDOC series, vol. 1178. Vienna: International Atomic Energy Agency; 2000.
Al-Abyad M, Spahn I, Sudár S, Morsy M, Comsan MNH, Csikai J, Qaim SM, Coenen HH. Nuclear data for production of the therapeutic radionuclides 32P, 64Cu, 67Cu, 89Sr, 90Y and 153Sm via the (n,p) reaction: evaluation of excitation function and its validation via integral cross-section measurement using a 14MeV d(Be) neutron source. Appl Radiat Isot. 2006;64:717–24.
Spahn I, Coenen HH, Qaim SM. Enhanced production possibility of the therapeutic radionuclides 64Cu, 67Cu and 89Sr via (n,p) reactions induced by fast spectral neutrons. Radiochim Acta. 2004;92:183–6.
DeLorme K, Engle J, Kowash B, Nortier F, Birnbaum E, McHale S, Clinton J, John K, Jackman K, Marus L. Production potential of Sc-47 using spallation neutrons at the Los Alamos isotope production facility. J Nucl Med. 2014;55:196.
Bauer GS. Physics and technology of spallation neutron sources. Nucl Instrum Methods Phys Res, Sect A. 2001;463:505–43.
Baum RP, Singh A, Benešová M, Vermeulen C, Gnesin S, Koster U, Johnston K, Muller D, Senftleben S, Kulkarni HR, Turler A, Schibli R, Prior JO, van der Meulen NP, Muller C. Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC. Dalton Trans. 2017;46:14638–46.
Müller C, Zhernosekov K, Köster U, Johnston K, Dorrer H, Hohn A, van der Walt NT, Türler A, Schibli R. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β−-radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative. J Nucl Med. 2012;53:1951–9.
Herzog H, Rösch F, Stöcklin G, Lueders C, Qaim SM, Feinendegen LE. Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics. J Nucl Med. 1993;34:2222–6.
Rösch F, Herzog H, Qaim S. The beginning and development of the theranostic approach in nuclear medicine, as exemplified by the radionuclide pair 86Y and 90Y. Pharmaceuticals. 2017;10:56.
Townsend DW, Beyer T, Kinahan P, Meltzer CC, Brun T, Nutt R. The SMART scanner: a combined PET/CT tomograph for clinical oncology. Radiology. 1998;209P:169–70.
Bailey DL, Barthel H, Beuthin-Baumann B, Beyer T, Bisdas S, Boellaard R, Czernin J, Drzezga A, Ernemann U, Franzius C, Guckel B, Handgretinger R, Hartenbach M, Hellwig D, Nadel H, Nekolla SG, Pfluger T, Pichler BJ, Quick HH, Sabri O, Sattler B, Schafer J, Schick F, Siegel BA, Schlemmer HP, Schwenzer NF, van den Hoff J, Veit-Haibach P, Wehrl HF. Combined PET/MR: where are we now? Summary report of the second international workshop on PET/MR imaging, 8-12 Apr 2013, Tubingen, Germany. Mol Imaging Biol. 2014;16:295–310.
Schmand M, Burbar Z, Corbeil J, Zhang N, Michael C, Byars L, Eriksson L, Grazioso R, Martin M, Moor A, Camp J, Matschl V, Ladebeck R, Renz W, Fischer H, Jattke K, Schnur G, Rietsch N, Bendriem B, Heiss W-D. BrainPET: first human tomograph for simultaneous (functional) PET and MR imaging. J Nucl Med. 2007;48:45P.
Zaidi H, Ojha N, Morich M, Griesmer J, Hu Z, Maniawski P, Ratib O, Izquierdo-Garcia D, Fayad ZA, Shao L. Design and performance evaluation of a whole-body Ingenuity TF PET-MRI system. Phys Med Biol. 2011;56:3091–106.
Kiani A, Esquevin A, Lepareur N, Bourguet P, Le Jeune F, Gauvrit JY. Main applications of hybrid PET-MRI contrast agents: a review. Contrast Media Mol Imaging. 2016;11:92–8.
Ermert J. 18F-labelled intermediates for radiosynthesis by modular build-up reactions: newer developments. Biomed Res Int. 2014;2014:812973.
Miller PW, Long NJ, Vilar R, Gee AD. Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Angew Chem Int Ed Engl. 2008;47:8998–9033.
Qaim SM, Clark JC, Crouzel C, Guillaume M, Helmeke HJ, Nebeling B, Pike VW, Stöcklin G. PET radionuclide production. In: Stöcklin G, Pike VW, editors. Radiopharmaceuticals for positron emission tomography – methodological aspects. Dordrecht: Kluwer; 1993. p. 1–42.
Urch DS. Radiochemistry. Annu Rep A. 2013;109:468–83.
IAEA. Nuclear data for the production of therapeutic radionuclides. Technical reports series. International Atomic Energy Agency: Vienna; 2011.
Vértes A, Nagy S, Klencsár Z, Lovas RG, Rösch F. Handbook of nuclear chemistry. Dordrecht: Kluwer; 2003.
Landais P, Crouzel C. A new synthesis of carbon-11 labelled phosgene. Appl Radiat Isot. 1987;38:297–300.
Crouzel C, Långström B, Pike VW, Coenen HH. Recommendations for a practical production of [11C]methyl iodide. Appl Radiat Isot. 1987;38:601–3.
Suzuki K, Yamazaki T, Sasaki M, Kubodera A. Specific activity of [11C]CO2generated in a N2 gas target: effect of irradiation dose, irradiation history, oxygen content and beam energy. Radiochim Acta. 2000;88:211–5.
Clark JC, Crouzel C, Meyer GJ, Strijckmans K. Current methodology for oxygen-15 production for clinical use. Int J Appl Radiat Isot. 1987;38:597–600.
Powell J, O’Neil JP. Production of [15O]water at low-energy proton cyclotrons. Appl Radiat Isot. 2006;64:755–9.
Gómez-Vallejo V, Gaja V, Gona KB, Llop J. Nitrogen-13: historical review and future perspectives. J Label Compd Radiopharm. 2014;57:244–54.
Schlyer DJ. Production of radionuclides in accelerators. In: Welch MJ, Redvanly CS, editors. Handbook of radiopharmaceuticals. New York, NY: John Wiley & Sons; 2003. p. 1–70.
Bishop A, Satyamurthy N, Bida G, Phelps M, Barrio JR. Identification and quantitation of gaseous compounds of fluorine generated in [18F]F2 target systems. Nucl Med Biol. 1996;23:391–405.
Hess E, Blessing G, Coenen HH, Qaim SM. Improved target system for production of high purity [18F]fluorine via the 18O(p,n)18F reaction. Appl Radiat Isot. 2000;52:1431–40.
Roberts AD, Oakes TR, Nickles RJ. Development of an improved target for [18F]F2 production. Appl Radiat Isot. 1995;46:87–91.
Bergman J, Solin O. Fluorine-18-labeled fluorine gas for synthesis of tracer molecules. Nucl Med Biol. 1997;24:677–83.
Eppard E, de la Fuente A, Benešová M, Khawar A, Bundschuh RA, Gärtner FC, Kreppel B, Kopka K, Essler M, Rosch F. Clinical translation and first in-human use of [44Sc]Sc-PSMA-617 for PET imaging of metastasized castrate-resistant prostate cancer. Theranostics. 2017;7:4359–69.
Hernandez R, Valdovinos HF, Yang Y, Chakravarty R, Hong H, Barnhart TE, Cai W. 44Sc: an attractive isotope for peptide-based PET imaging. Mol Pharm. 2014;11:2954–61.
Khawar A, Eppard E, Sinnes JP, Roesch F, Ahmadzadehfar H, Kurpig S, Meisenheimer M, Gaertner FC, Essler M, Bundschuh RA. 44Sc Sc-PSMA-617 biodistribution and dosimetry in patients with metastatic castration-resistant prostate carcinoma. Clin Nucl Med. 2018;43:323–30.
Nagy G, Szikra D, Trencsényi G, Fekete A, Garai I, Giani AM, Negri R, Masciocchi N, Maiocchi A, Uggeri F, Tóth I, Aime S, Giovenzana GB, Baranyai Z. AAZTA: an ideal chelating agent for the development of 44Sc PET imaging agents. Angew Chem. 2017;129:2150–4.
Carzaniga TS, Auger M, Braccini S, Bunka M, Ereditato A, Nesteruk KP, Scampoli P, Türler A, van der Meulen N. Measurement of 43Sc and 44Sc production cross-section with an 18 MeV medical PET cyclotron. Appl Radiat Isot. 2017;129:96–102.
Synowiecki MA, Perk LR, Nijsen JFW. Production of novel diagnostic radionuclides in small medical cyclotrons. EJNMMI Radiopharm Chem. 2018;3:3.
Lin Y-J, Koretsky AP. Manganese ion enhances T1-weighted MRI during brain activation: an approach to direct imaging of brain function. Magn Reson Med. 1997;38:378–88.
Topping GJ, Schaffer P, Hoehr C, Ruth TJ, Sossi V. Manganese-52 positron emission tomography tracer characterization and initial results in phantoms and in vivo. Med Phys. 2013;40:042502.
Abe K, Iizuka A, Hasegawa A, Morozumi S. Induced radioactivity of component materials by 16-MeV protons and 30-MeV alpha particles. J Nucl Mater. 1984;123:972–6.
Dmitriev PP. Systematics of nuclear reaction yields for thick target at 22 mev proton energy. Vop At Nauki i Tekhn SerYadernye Konstanty. 1983;2:57.
Aslam MN, Qaim SM. Nuclear model analysis of excitation functions of proton, deuteron and α-particle induced reactions on nickel isotopes for production of the medically interesting copper-61. Appl Radiat Isot. 2014;89:65–73.
Aslam MN, Sudár S, Hussain M, Malik AA, Shah HA, Qaim SM. Charged particle induced reaction cross section data for production of the emerging medically important positron emitter 64Cu: a comprehensive evaluation. Radiochim Acta. 2009;97:669–86.
Szelecsényi F, Blessing G, Qaim SM. Excitation functions of proton induced nuclear reactions on enriched 61Ni and 64Ni: possibility of production of no-carrier-added 61Cu and 64Cu at a small cyclotron. Appl Radiat Isot. 1993;44:575–80.
Watanabe S, Iida Y, Suzui N, Katabuchi T, Ishii S, Kawachi N, Hanaoka H, Watanabe S, Matsuhashi S, Endo K, Ishioka NS. Production of no-carrier-added 64Cu and applications to molecular imaging by PET and PETIS as a biomedical tracer. J Radioanal Nucl Chem. 2009;280:199–205.
Szelecsényi F, Boothe TE, Takács S, Tárkányi F, Tavano E. Evaluated cross section and thick target yield data bases of Zn+p processes for practical applications. Appl Radiat Isot. 1998;49:1005–32.
EXFOR (2018) Experimental nuclear reaction data (EXFOR). https://www-nds.iaea.org/exfor/exfor.htm. Accessed 2018.
Takács S, Ditrói F, Szűcs Z, Haba H, Komori Y, Aikawa M, Saito M. Crosschecking of alpha particle monitor reactions up to 50 MeV. Nucl Instrum Methods Phys Res, Sect B. 2017;397:33–8.
Tárkányi F, Takács S, Ditrói F, Hermanne A, Sonck M, Shubin Y. Excitation functions of deuteron induced nuclear reactions on natural zinc up to 50 MeV. Nucl Instrum Methods Phys Res, Sect B. 2004;217:531–50.
Khandaker MU, Haba H, Murakami M, Otuka N. Production cross-sections of long-lived radionuclides in deuteron-induced reactions on natural zinc up to 23 MeV. Nucl Instrum Methods Phys Res, Sect B. 2015;346:8–16.
Isabel M, Prata M. Gallium-68: a new trend in PET radiopharmacy. Curr Radiopharm. 2012;5:142–9.
Lambrecht RM, Sajjad M. Accelerator-derived radionuclide generators. Radiochim Acta. 1988;43:171–9.
Loc’h C, Mazièré B, Comar D. A new generator for ionic gallium-68. J Nucl Med. 1980;21:171–3.
Nakayama M, Haratake M, Koiso T, Ishibashi O, Harada K, Nakayama H, Sugii A, Yahara S, Arano Y. Separation of 68Ga from 68Ge using a macroporous organic polymer containing N-methylglucamine groups. Anal Chim Acta. 2002;453:135–41.
Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, Jahn M, Jennewein M, Rosch F. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007;48:1741–8.
Takács S, Tárkányi F, Hermanne A, Paviotti de Corcuera R. Validation and upgrading of the recommended cross section data of charged particle reactions used for production of PET radioisotopes. Nucl Instrum Methods Phys Res, Sect B. 2003;211:169–89.
Basile D, Birattari C, Bonardi M, Goetz L, Sabbioni E, Salomone A. Excitation functions and production of arsenic radioisotopes for environmental toxicology and biomedical purposes. Int J Appl Radiat Isot. 1981;32:403–10.
Evans CD, LaDow K, Schumann BL, Savage RE, Caruso J, Vonderheide A, Succop P, Talaska G. Effect of arsenic on benzo a pyrene DNA adduct levels in mouse skin and lung. Carcinogenesis. 2004;25:493–7.
Wang Z-Y. Arsenic compounds as anticancer agents. Cancer Chemother Pharmacol. 2001;48:S72–6.
Jennewein M, Qaim SM, Kulkarni RV, Mason RP, Hermanne A, Rosch F. A no-carrier-added 72Se/72As radionuclide generator based on solid phase extraction. Radiochim Acta. 2005;93:579–83.
Horiguchi T, Kumahora H, Inoue H, Yoshizawa Y. Excitation function of Ge(p,xnyp) reactions and production of 68Ge. Int J Appl Radiat Isot. 1983;34:1531–5.
Spahn I, Steyn GF, Nortier FM, Coenen HH, Qaim SM. Excitation functions of natGe(p,xn)71,72,73,74As reactions up to 100MeV with a focus on the production of 72As for medical and 73As for environmental studies. Appl Radiat Isot. 2007;65:1057–64.
Takács S, Takács MP, Hermanne A, Tárkányi F, Adam-Rebeles R. Excitation functions of longer lived radionuclides formed by deuteron irradiation of germanium. Nucl Instrum Methods Phys Res, Sect B. 2014;336:81–95.
Didik VA, Malkovich RS, Skoryatina EA, Kozlovskii VV. Experimental determination of the cross sections of nuclear reactions by the method of analysis of the concentration profiles of transmutation nuclides. At Energy. 1994;77:570–2.
Takács S, Takács MP, Ditrói F, Aikawa M, Haba H, Komori Y. Activation cross sections of longer-lived radionuclides produced in germanium by alpha particle irradiation. Nucl Instrum Methods Phys Res, Sect B. 2016;383:213–26.
Shehata MM, Scholten B, Spahn I, Coenen HH, Qaim SM. Separation of radioarsenic from irradiated germanium oxide targets for the production of 71As and 72As. J Radioanal Nucl Chem. 2011;287:435–42.
Mushtaq A, Qaim SM, Stöcklin G. Production of 73Se via (p,3n) and (d,4n) reactions on arsenic. Int J Appl Radiat Isot. 1988;39:1085–91.
Faßbender M, de Villiers D, Nortier M, van der Walt N. The natBr(p,x)73,75Se nuclear processes: a convenient route for the production of radioselenium tracers relevant to amino acid labelling. Appl Radiat Isot. 2001;54:905–13.
Mushtaq A, Qaim SM. Excitation functions of α- and 3He-particle induced nuclear reactions on natural germanium: evaluation of production routes for 73Se. Radiochim Acta. 1990;50:27–31.
Blessing G, Lavi N, Qaim SM. Production of 73Se via the 70Ge(α, n)-process using high current target materials. Int J Appl Radiat Isot. 1992;43:455–61.
Qaim SM, Spahn I, Scholten B, Neumaier B. Uses of alpha particles, especially in nuclear reaction studies and medical radionuclide production. Radiochim Acta. 2016;104:601–24.
Qaim SM, Spahn I. Development of novel radionuclides for medical applications. J Label Compd Radiopharm. 2018;61:126–40.
Qaim SM, Blessing G, Tárkányi F, Lavi N, Bräutigam W, Scholten B, Stöcklin B. Production of longer-lived positron emitters 73Se, 82mRb and 124I. In: 14th international conference on cyclotrons and their applications (CYCLOTRONS 95), 1995. Cape Town: Faure; 1995.
Qaim SM, Bisinger T, Hilgers K, Nayak D, Coenen HH. Positron emission intensities in the decay of 64Cu-, 76Br and 124I. Radiochim Acta. 2007;95:67–73.
Ribeiro MJ, Almeida P, Strul D, Ferreira N, Loc’h C, Brulon V, Trebossen R, Maziere B, Bendriem B. Comparison of fluorine-18 and bromine-76 imaging in positron emission tomography. Eur J Nucl Med. 1999;26:758–66.
Rowland DJ, McCarthy TJ, Welch MJ. Radiobromine for imaging and therapy. In: Welch MJ, Redvanly CS, editors. Handbook of radiopharmaceuticals. New York, NY: John Wiley & Sons; 2003. p. 441–65.
Qaim SM. Recent developments in the production of 18F, 75,76,77Br and 123I. Appl Radiat Isot. 1986;37:803–10.
Spahn I, Steyn GF, Vermeulen C, Kovács Z, Szelecsényi F, Shehata MM, Spellerberg S, Scholten B, Coenen HH, Qaim SM. New cross section measurements for the production of the Auger electron emitters 77Br and 80mBr. Radiochim Acta. 2010;98:749–55.
Scholten B, Takács S, Tárkányi F, Coenen Heinz H, Qaim Syed M. Excitation functions of deuteron induced nuclear reactions on enriched 78Kr with particular relevance to the production of 76Br. Radiochim Acta. 2004;92(4–6):203–7.
Hassan HE, Qaim SM, Shubin Y, Azzam A, Morsy M, Coenen HH. Experimental studies and nuclear model calculations on proton-induced reactions on natSe, 76Se and 77Se with particular reference to the production of the medically interesting radionuclides 76Br and 77Br. Appl Radiat Isot. 2004;60:899–909.
Breunig K, Spahn I, Spellerberg S, Coenen HH. Production of no-carrier-added radiobromine: new nickel selenide target and optimized separation by dry distillation. Radiochim Acta. 2015;103:397–402.
Hagemann CE, Ghotbi AA, Kjær A, Hasbak P. Quantitative myocardial blood flow with Rubidium-82 PET: a clinical perspective. Am J Nucl Med Mol Imaging. 2015;5:457–68.
Chatal J-F, Rouzet F, Haddad F, Bourdeau C, Mathieu C, Le Guludec D. Story of rubidium-82 and advantages for myocardial perfusion PET imaging. Front Med. 2015;2:65.
Phillips DR, Peterson EJ, Taylor WA, Jamriska DJ, Hamilton VT, Kitten JJ, Valdez FO, Salazar LL, Pitt LR, Heaton RC, Kolsky KL, Mausner LF, Kurczak S, Zhuikov BL, Kokhanyuk VM, Konyakhin NA, Nortier FM, van der Walt TN, Hanekom J, Sosnowski KM, Carty JS. Production of strontium-82 for the Cardiogen® PET generator: a project of the Department of Energy Virtual Isotope Center. Radiochim Acta. 2000;88:149–55.
Tárkányi F, Qaim SM, Stöcklin G. Excitation functions of high-energy 3He and α-particle induced nuclear reactions on natural krypton with special reference to the production of 82Sr. Appl Radiat Isot. 1990;41:91–5.
Zaneb H, Hussain M, Amjed N, Qaim SM. Nuclear model analysis of excitation functions of proton induced reactions on 86Sr, 88Sr and natZr: evaluation of production routes of 86Y. Appl Radiat Isot. 2015;104:232–41.
Rösch F, Qaim SM, Stöcklin G. Nuclear data relevant to the production of the positron emitting radioisotope 86Y via the 86Sr(p,n)- and natRb(3He,xn)-processes. Radiochim Acta. 1993;61:1–8.
Kettern K, Linse KH, Spellerberg S, Coenen HH, Qaim SM. Radiochemical studies relevant to the production of 86Y and 88Y at a small-sized cyclotron. Radiochim Acta. 2002;90:845–9.
Rösch F, Qaim SM, Stöcklin G. Production of the positron emitting radioisotope 86Y for nuclear medical application. Appl Radiat Isot. 1993;44:677–81.
Oehlke E, Hoehr C, Hou X, Hanemaayer V, Zeisler S, Adam MJ, Ruth TJ, Celler A, Buckley K, Benard F, Schaffer P. Production of Y-86 and other radiometals for research purposes using a solution target system. Nucl Med Biol. 2015;42:842–9.
Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Design Dev Ther. 2016;10:465–81.
Fischer G, Seibold U, Schirrmacher R, Wängler B, Wängler C. 89Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges. Molecules. 2013;18:6469–90.
Meijs WE, Herscheid JDM, Haisma HJ, Wijbrandts R, van Langevelde F, Van Leuffen PJ, Mooy R, Pinedo HM. Production of highly pure no-carrier added 89Zr for the labelling of antibodies with a positron emitter. Appl Radiat Isot. 1994;45:1143–7.
McKnight BN, Viola-Villegas NT. 89Zr-ImmunoPET companion diagnostics and their impact in clinical drug development. J Label Compd Radiopharm. 2018; https://doi.org/10.1002/jlcr.3605.
Severin GW, Engle JW, Barnhart TE, Nickles RJ. 89Zr radiochemistry for positron emission tomography. Med Chem. 2011;7:389–94.
Omara HM, Hassan KF, Kandil SA, Hegazy FE, Saleh ZA. Proton induced reactions on 89Y with particular reference to the production of the medically interesting radionuclide 89Zr. Radiochim Acta. 2009;97:467–71.
Wright CL, Zhang J, Tweedle MF, Knopp MV, Hall NC. Theranostic imaging of yttrium-90. BioMed Res Int. 2015;2015:481279.
Minarik D, Sjogreen-Gleisner K, Linden O, Wingardh K, Tennvall J, Strand SE, Ljungberg M. 90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy. J Nucl Med. 2010;51:1974–8.
Elschot M, Nijsen JFW, Dam AJ, de Jong H. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS One. 2011;6:e26174.
IAEA. Therapeutic radionuclide generators: 90Sr/90Y and 188W/188Re generators. Technical reports series. Vienna: International Atomic Energy Agency; 2009.
Delaunay-Olkowsky J, Strohal P, Cindro N. Total reaction cross sections of photon induced reactions. Nucl Phys. 1963;47:266–72.
Flynn DS, Hershberger RL, Gabbard F. Sub-Coulomb proton absorption for isotopes of zirconium and molybdenum. Phys Rev C. 1979;20:1700–5.
Skakun EA, Batij VG, Rakivnenko YN, Rastrepin OA. Excitation functions and isomer ratio for up-to-9 MeV proton interactions with Zr and Mo isotope nuclei. Yad Fiz. 1987;46:28–39.
Uddin MS, Hagiwara M, Tarkanyi F, Ditroi F, Baba M. Experimental studies on the proton-induced activation reactions of molybdenum in the energy range 22–67MeV. Appl Radiat Isot. 2004;60:911–20.
Eckelman WC. Unparalleled contribution of technetium-99m to medicine over 5 decades. JACC Cardiovasc Imaging. 2009;2:364–8.
Einstein AJ. Breaking America’s dependence on imported molybdenum. JACC Cardiovasc Imaging. 2009;2:369–71.
IAEA. Radiotracer generators for industrial applications. IAEA radiation technology series. Vienna: International Atomic Energy Agency; 2013.
Van Noorden R. Radioisotopes: the medical testing crisis. Nature. 2013;504:202–4.
Beaver JE, Hupf HB. Production of 99mTc on a medical cyclotron: a feasibility study. J Nucl Med. 1971;12:739–41.
Qaim SM, Sudar S, Scholten B, Koning AJ, Coenen HH. Evaluation of excitation functions of 100Mo(p,d+pn)99Mo and 100Mo(p,2n)99mTc-reactions: estimation of long-lived Tc-impurity and its implication on the specific activity of cyclotron-produced 99mTc. Appl Radiat Isot. 2014;85:101–13.
Bénard F, Buckley KR, Ruth TJ, Zeisler SK, Klug J, Hanemaayer V, Vuckovic M, Hou X, Celler A, Appiah J-P, Valliant J, Kovacs MS, Schaffer P. Implementation of multi-curie production of 99mTc by conventional medical cyclotrons. J Nucl Med. 2014;55:1017–22.
Schaffer P, Bénard F, Bernstein A, Buckley K, Celler A, Cockburn N, Corsaut J, Dodd M, Economou C, Eriksson T, Frontera M, Hanemaayer V, Hook B, Klug J, Kovacs M, Prato FS, McDiarmid S, Ruth TJ, Shanks C, Valliant JF, Zeisler S, Zetterberg U, Zavodszky PA. Direct production of 99mTc via 100Mo(p,2n) on small medical cyclotrons. Phys Procedia. 2015;66:383–95.
Chen K, Cui M. Recent progress in the development of metal complexes as b-amyloid imaging probes in the brain. Medchemcomm. 2017;8:1393–407.
Takács S, Tárkányi F, Hermanne A. Validation and upgrading of the recommended cross-section data of charged particle reactions: gamma emitter radioisotopes. Nucl Instrum Methods Phys Res, Sect B. 2005;240:790–802.
Coenen HH, Mertens J, Mazieère B, Bläuenstein P, Emond P, Frangin Y, Guilloteau D, Gysemans M, Holschbach M, Loc’h C, Schubiger AP, Qaim SM. Radioionidation reactions for radio pharmaceuticals: compendium for effective synthesis strategies. New York, NY: Springer; 2006. p. 1–101.
IAEA. Final report of a coordinated research project “Charged-particle cross section database for medical radioisotope production”: diagnostic radioisotopes and monitor reactions. IAEA-TECDOC-1211. Vienna: International Atomic Energy Agency; 2001.
Hassan KF, Qaim SM, Saleh ZA, Coenen HH. Alpha-particle induced reactions on natsb and 121Sb with particular reference to the production of the medically interesting radionuclide 124I. Appl Radiat Isot. 2006;64:101–9.
Herzog H, Tellmann L, Scholten B, Coenen HH, Qaim SM. PET imaging problems with the non-standard positron emitters yttrium-86 and iodine-124. Q J Nucl Med Mol Imaging. 2008;52:159–65.
Tárkányi F, Takács S, Király B, Szelecsényi F, Andó L, Bergman J, Heselius SJ, Solin O, Hermanne A, Shubin YN, Ignatyuk AV. Excitation functions of 3He- and α-particle induced nuclear reactions on natSb for production of medically relevant 123I and 124I radioisotopes. Appl Radiat Isot. 2009;67:1001–6.
Aslam MN, Sudar S, Hussain M, Malik AA, Shah HA, Qaim SM. Evaluation of excitation functions of proton and deuteron induced reactions on enriched tellurium isotopes with special relevance to the production of iodine-124. Appl Radiat Isot. 2010;68:1760–73.
IAEA. Nuclear medicine in thyroid cancer management: a practical approach. IAEA, 2009. IAEA TECDOC-1608. Vienna: International Atomic Energy Agency; 2009.
Shapiro B, Gross MD. Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG: clinical implications of the use of 123I-MIBG. Med Pediatr Oncol. 1987;15:170–7.
Qaim SM. Cyclotron production of medical radionuclides. In: Vertes A, et al., editors. Handbook of nuclear chemsitry. Dordrecht: Kluwer; 2003. p. 47–79.
Raleigh DR, Seymour ZA, Tomlin B, Theodosopoulos PV, Berger MS, Aghi MK, Geneser SE, Krishnamurthy D, Fogh SE, Sneed PK, McDermott MW. Resection and brain brachytherapy with permanent iodine-125 sources for brain metastasis. J Neurosurg. 2017;126:1749–55.
Huang H, Xu S, Li F, Du Z, Wang L. Clinical application of computed tomography-guided 125I seed interstitial implantation for head and neck cancer patients with unmanageable cervical lymph node metastases. Eur J Med Res. 2016;21:18.
Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, Thomsen HS. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J. 2012;5:82–8.
Denzler FO, Lebedev NA, Novgorodov AF, Rösch F, Qaim SM. Production and radiochemical separation of 147Gd. Appl Radiat Isot. 1997;48:319–26.
Nayak D, Lahiri S, Ramaswami A, Manohor SB. Separation of no-carrier added Gd-147,Gd-149 and Eu-147 produced in 70 MeV B-11 irradiated praseodymium foil target. Radiochim Acta. 1999;87:93–6.
West HI, Lanier RG, Mustafa MG, Nuckolls RN, Frehaut J, Adam A, Philis CA. Proton and deuteron excitation functions for Eu-151 and Eu-153. Brookhaven Natl Lab Rep. 1989;42382:87–90.
Takács S, Tárkányi F, Hermanne A, Adam-Rebeles R, Takács MP. Excitation functions for the formation of longer lived isotopes by deuteron irradiation of Europium. Nucl Instrum Methods Phys Res, Sect B. 2013;310:54–66.
Bao ZY, Beer H, Kappeler F, Voss F, Wisshak K, Rauscher T. Neutron cross sections for nucleosynthesis studies. At Data Nucl Data Tables. 2000;76:70–154.
IAEA. Optimization of production and quality control of therapeutic radionuclides and radiopharmaceuticals. AEA TECDOC series I. Vienna: International Atomic Energy Agency; 1999.
Qaim SM, Spahn I, Kandil SA, Coenen HH. Nuclear data for production of 88Y, 140Nd, 153Sm and 169Yb via novel routes. Radiochim Acta. 2007;95:313–7.
Dash A, Chakraborty S, Pillai MRA, Knapp FF. Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm. 2015;30:47–71.
Hermanne A, Takacs S, Goldberg MB, Lavie E, Shubin YN, Kovalev S. Deuteron-induced reactions on Yb: measured cross sections and rationale for production pathways of carrier-free, medically relevant radionuclides. Nucl Instrum Methods Phys Res, Sect B. 2006;247:223–31.
Manenti S, Bonardi ML, Gini L, Groppi F. Physical optimization of production by deuteron irradiation of high specific activity 177gLu suitable for radioimmunotherapy. Nucl Med Biol. 2014;41:407–9.
Pillai MRA, Venkatesh M, Banerjee S, Samuel G, Kothari K, Dash A, Unni PR, Korde A, Bapat K, Pandey U, Das T, Chakraborty S, Mukherjee A, Sharma HD. Labeling techniques of biomolecules for targeted radiotherapy. IAEA-TECDOC-1359. Vienna: IAEA; 2003. p. 107–22.
Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57:1170–6.
Goyal J, Antonarakis ES. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett. 2012;323:135–46.
Miyahara H, Wurdiyanto G, Nagata H, Yoshida A, Yanagida K, Mori C. Precise measurements of the gamma-ray emission probabilities of 186Re and 188Re. Appl Radiat Isot. 2000;52:573–9.
Mastren T, Radchenko V, Bach HT, Balkin ER, Birnbaum ER, Brugh M, Engle JW, Gott MD, Guthrie J, Hennkens HM, John KD, Ketring AR, Kuchuk M, Maassen JR, Naranjo CM, Nortier FM, Phelps TE, Jurisson SS, Wilbur DS, Fassbender ME. Bulk production and evaluation of high specific activity 186gRe for cancer therapy using enriched 186WO3 targets in a proton beam. Nucl Med Biol. 2017;49:24–9.
Guerra Liberal FDC, Tavares AAS, Tavares JMRS. Palliative treatment of metastatic bone pain with radiopharmaceuticals: a perspective beyond Strontium-89 and Samarium-153. Appl Radiat Isot. 2016;110:87–99.
Neves M, Kling A, Lambrecht RM. Radionuclide production for therapeutic radiopharmaceuticals. Appl Radiat Isot. 2002;57:657–64.
Hussain M, Sudar S, Aslam MN, Malik AA, Ahmad R, Qaim SM. Evaluation of charged particle induced reaction cross section data for production of the important therapeutic radionuclide 186Re. Radiochim Acta. 2010;98:385–95.
Lewis RE, Eldridge JS. Production of 70-day Tungsten-188 and development of a 17 hour rhenium-188 radioisotope generator. J Nucl Med. 1966;7:804.
Knapp FF, Callahan AP, Beets AL, Mirzadeh S, Hsieh BT. Processing of reactor-produced 188W for fabrication of clinical scale alumina-based 188W/188Re generators. Appl Radiat Isot. 1994;45:1123–8.
Uddin MS, Scholten B, Hermanne A, Sudár S, Coenen HH, Qaim SM. Radiochemical determination of cross sections of α-particle induced reactions on 192Os for the production of the therapeutic radionuclide 193mPt. Appl Radiat Isot. 2010;68:2001–6.
Hilgers K, Coenen HH, Qaim SM. Production of the therapeutic radionuclides 193mPt and 195mPt with high specific activity via α-particle-induced reactions on 192Os. Appl Radiat Isot. 2008;66:545–51.
Takács S, Ditrói F, Szűcs Z, Aikawa M, Haba H, Komori Y, Saito M. Measurement of activation cross sections of alpha particle induced reactions on iridium up to an energy of 50 MeV. Appl Radiat Isot. 2018;136:133–42.
Meyer GJ. Astatine. J Label Compd Radiopharm. 2018;61:154–64.
Vaidyanathan G, Zalutsky MR. Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. Curr Radiopharm. 2011;4:283–94.
Vaidyanathan G, Zalutsky MR. Astatine radiopharmaceuticals: prospects and problems. Curr Radiopharm. 2008;1:177–96.
Zalutsky MR, Pruszynski M. Astatine-211: production and availability. Curr Radiopharm. 2011;4:177–85.
Hermanne A, Tárkányi F, Takács S, Szücs Z, Shubin YN, Dityuk AI. Experimental study of the cross-sections of α-particle induced reactions on 209Bi. Appl Radiat Isot. 2005;63:1–9.
Miederer M, Scheinberg DA, McDevitt MR. Realizing the potential of the actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev. 2008;60:1371–82.
Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, Morgenstern A. Targeted alpha-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795–802.
Alfassi ZB, Bonardi M, Groppi F, Menapace E. A new alpha-emitter for nuclear medicine: 230U. J Radioanal Nucl Chem. 2006;270:483–7.
Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem. 2005;77:6288–91.
Apostolidis C, Molinet R, McGinley J, Abbas K, Mollenbeck J, Morgenstern A. Cyclotron production of Ac-225 for targeted alpha therapy. Appl Radiat Isot. 2005;62:383–7.
Weidner JW, Mashnik SG, John KD, Hemez F, Ballard B, Bach H, Birnbaum ER, Bitteker LJ, Couture A, Dry D, Fassbender ME, Gulley MS, Jackman KR, Ullmann JL, Wolfsberg LE, Nortier FM. Proton-induced cross sections relevant to production of 225Ac and 223Ra in natural thorium targets below 200 MeV. Appl Radiat Isot. 2012;70:2602–7.
Melville G, Meriarty H, Metcalfe P, Knittel T, Allen BJ. Production of Ac-225 for cancer therapy by photon-induced transmutation of Ra-226. Appl Radiat Isot. 2007;65:1014–22.
Chen X, Ji M, Fisher DR, Wai CM. Ionizable calixarene-crown ethers with high selectivity for radium over light alkaline earth metal ions. Inorg Chem. 1999;38:5449–52.
Guseva LI. A tandem generator system for production of 223Ra and 211Pb/211Bi in DTPA solutions suitable for potential application in radiotherapy. J Radioanal Nucl Chem. 2009;281:577.
Westrøm S, Malenge M, Jorstad Ida S, Napoli E, Bruland Øyvind S, Bønsdorff Tina B, Larsen Roy H. Ra-224 labeling of calcium carbonate microparticles for internal α-therapy: preparation, stability, and biodistribution in mice. J Label Compd Radiopharm. 2018;61:472–86.
Abou DS, Pickett J, Mattson JE, Thorek DLJ. A Radium-223 microgenerator from cyclotron-produced trace Actinium-227. Appl Radiat Isot. 2017;119:36–42.
Mokhodoeva O, Guseva L, Dogadkin N. Isolation of generator-produced 223Ra in 0.9-% NaCl solutions containing EDTA for direct radiotherapeutic studies. J Radioanal Nucl Chem. 2015;304:449–53.
Soderquist CZ, McNamara BK, Fisher DR. Production of high-purity radium-223 from legacy actinium-beryllium neutron sources. Curr Radiopharm. 2012;5:244–52.
Larsen R, Bruland O (2006) Thorium-227 for use in radiotherapy of soft tissue disease Patent US 20060228297 A1
Transparency Market Research (2018) Radiopharmaceutical market will exhibit a CAGR of 5.4% between 2017 and 2024. http://www.sbwire.com/press-releases/radiopharmaceutical-market/release-983778.htm
Schwochau K. Technetium: chemistry and radiopharmaceutical applications technetium: chemistry and radiopharmaceutical applications. Weinheim: Wiley; 2000.
Papagiannopoulou D. Technetium-99m radiochemistry for pharmaceutical applications. J Label Compd Radiopharm. 2017;60:502–20.
Blower PJ, Kettle AG, O’Doherty MJ, Coakley AJ, Knapp FF. 99mTc(V)DMSA quantitatively predicts 188Re(V)DMSA distribution in patients with prostate cancer metastatic to bone. Eur J Nucl Med. 2000;27:1405–9.
Alberto R, Schibli R, Egli A, Schubiger AP, Abram U, Kaden TA. A novel organometallic aqua complex of technetium for the labeling of biomolecules: synthesis of [99mTc(OH2)3(CO)3]+ from [99mTcO4]− in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc. 1998;120:7987–8.
Satpati D, Mallia M, Kothari K, Pillai MRA. Comparative evaluation of 99mTc-(H2O)3(CO)3+ precursor synthesised by conventional method and by using carbonyl kit. J Label Compd Radiopharm. 2004;47:657–68.
Banerjee SR, Maresca KP, Francesconi L, Valliant J, Babich JW, Zubieta J. New directions in the coordination chemistry of 99mTc: a reflection on technetium core structures and a strategy for new chelate design. Nucl Med Biol. 2005;32:1–20.
Piramoon M, Hosseinimehr SJ. The past, current studies and future of organometallic 99mTc(CO)3 labeled peptides and proteins. Curr Pharm Des. 2016;22:4854–67.
Schibli R, Schubiger PA. Current use and future potential of organometallic radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2002;29:1529–42.
Mindt TL, Muller C, Stuker F, Salazar JF, Hohn A, Mueggler T, Rudin M, Schibli R. A “click chemistry” approach to the efficient synthesis of multiple imaging probes derived from a single precursor. Bioconjug Chem. 2009;20:1940–9.
Mindt TL, Struthers H, Brans L, Anguelov T, Schweinsberg C, Maes V, Tourwe D, Schibli R. “Click to chelate”: synthesis and installation of metal chelates into biomolecules in a single step. J Am Chem Soc. 2006;128:15096–7.
Andros G, Harper PV, Lathrop KA, McCardle RJ. Pertechnetate-99m localization in man with applications to thyroid scanning and the study of thyroid physiology. J Clin Endocrinol Metab. 1965;25:1067.
Cho JY, Leveille R, Kao R, Rousset B, Parlow AF, Burak WE, Mazzaferri EL, Jhiang SM. Hormonal regulation of radioiodide uptake activity and Na+/I− symporter expression in mammary glands. J Clin Endocrinol Metab. 2000;85:2936–43.
Jovanovic V, Konstantinovska D, Milivojevic K, Bzenic J. Determination of radiochemical purity and pharmacokinetic parameters of 99mTc-sulphur colloid and 99mTc-Tin colloid. Nuklearmedizin. 1981;20:279–82.
Suga K. Technical and analytical advances in pulmonary ventilation SPECT with xenon-133 gas and Tc-99m-Technegas. Ann Nucl Med. 2002;16:303–10.
Fritzberg AR, Kasina S, Eshima D, Johnson DL. Synthesis and biological evaluation of technetium-99m MAG3 as a Hippuran replacement. J Nucl Med. 1986;27:111–6.
Noll B, Johannsen B, May K, Spies H. Preparation of the renal function and imaging agent 99mTc-MAG3 starting from S-unprotected mercaptoacetyltriglycine. Int J Appl Radiat Isot. 1992;43:899–901.
Erbas B, Tuncel M. Renal function assessment during peptide receptor radionuclide therapy. Semin Nucl Med. 2016;46:462–78.
Itoh K. 99mTc-MAG3: review of pharmacokinetics, clinical application to renal diseases and quantification of renal function. Ann Nucl Med. 2001;15:179–90.
Taylor RD, MacCoss M, Lawson ADG. Combining molecular scaffolds from FDA approved drugs: application to drug discovery. J Med Chem. 2017;60:1638–47.
Dekemp RA, Renaud JM, Klein R, Beanlands RSB. Radionuclide tracers for myocardial perfusion imaging and blood flow quantification. Cardiol Clin. 2016;34:37.
Heo J, Iskandrian AS. Technetium-labeled myocardial perfusion agents. Cardiol Clin. 1994;12:187–98.
Kailasnath P, Sinusas AJ. Comparison of Tl-201 with Tc-99m-labeled myocardial perfusion agents: technical, physiologic, and clinical issues. J Nucl Cardiol. 2001;8:482–98.
Kiat H, Berman DS, Maddahi J. Myocardial perfusion imaging using technetium-99m radiopharmaceuticals. Radiol Clin North Am. 1993;31:795.
Berman DS, Kiat H, Van Train K, Garcia E, Friedman J, Maddahi J. Technetium 99m sestamibi in the assessment of chronic coronary artery disease. Semin Nucl Med. 1991;21:190–212.
Taillefer R, Laflamme L, Dupras G, Picard M, Phaneuf D-C, Léveillé J. Myocardial perfusion imaging with 99mTc-methoxy-isobutyl-isonitrile (MIBI): comparison of short and long time intervals between rest and stress injections. Eur J Nucl Med. 1988;13:515–22.
Higley B, Smith FW, Smith T, Gemmell HG, Gupta PD, Gvozdanovic DV, Graham D, Hinge D, Davidson J, Lahiri A. Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med. 1993;34:30–8.
Shanoudy H, Raggi P, Beller GA, Soliman A, Ammermann EG, Kastner RJ, Watson DD. Comparison of technetium-99m tetrofosmin and thallium-201 single-photon emission computed tomographic imaging for detection of myocardial perfusion defects in patients with coronary artery disease. J Am Coll Cardiol. 1998;31:331–7.
Leonard J-P, Nowotnik DP, Neirinckx RD. Technetium-99m-d,1-HM-PAO: a new radiopharmaceutical for imaging regional brain perfusion using SPECT—a comparison with iodine-123 HIPDM. J Nucl Med. 1986;27:1819–23.
Léveillé J, Demonceau G, De Roo M, Rigo P, Taillefer R, Morgan RA, Kupranick D, Walovitch RC. Characterization of technetium-99m-l,l-ECD for brain perfusion imaging, part 2: biodistribution and brain imaging in humans. J Nucl Med. 1989;30:1902–10.
Vallabhajosula S, Zimmerman RE, Picard M, Stritzke P, Mena I, Hellman RS, Tikofsky RS, Stabin MG, Morgan RA, Goldsmith SJ. Technetium-99m ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects. J Nucl Med. 1989;30:599–604.
Walovitch RC, Hill TC, Garrity ST, Cheesman EH, Burgess BA, O’Leary DH, Watson AD, Ganey MV, Morgan RA, Williams SJ. Characterization of technetium-99m-L,L-ECD for brain perfusion imaging, part 1: pharmacology of technetium-99m ECD in nonhuman primates. J Nucl Med. 1989;30:1892–901.
Neirinckx RD, Burke JF, Harrison RC, Forster AM, Andersen AR, Lassen NA. The retention mechanism of technetium-99m-HM-PAO: intracellular reaction with glutathione. J Cereb Blood Flow Metab. 1988;8:S4–S12.
Suess E, Malessa S, Ungersböck K, Kitz P, Podreka I, Heimberger K, Hornykiewicz O, Deecke L. Technetium-99m-d, 1-hexamethylpropyleneamine oxime (HMPAO) uptake and glutathione content in brain tumors. J Nucl Med. 1991;32:1675–81.
Kung HF, Kung MP, Wey SP, Lin KJ, Yen TC. Clinical acceptance of a molecular imaging agent: a long march with [99mTc]TRODAT. Nucl Med Biol. 2007;34:787–9.
Kung M-P, Stevenson DA, Plössl K, Meegalla SK, Beckwith A, Essman WD, Mu M, Lucki I, Kung HF. [99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med. 1997;24:372–80.
Meegalla SK, Plössl K, Kung M-P, Stevenson DA, Mu KS, Liable-Sands LM, Rheingold AL, Kung HF. Specificity of diastereomers of [99mTc]TRODAT-1 as dopamine transporter imaging agents. J Med Chem. 1998;41:428–36.
Fallahi B, Esmaeili A, Beiki D, Oveisgharan S, Noorollahi-Moghaddam H, Erfani M, Tafakhori A, Rohani M, Fard-Esfahani A, Emami-Ardekani A, Geramifar P, Eftekhari M. Evaluation of 99mTc-TRODAT-1 SPECT in the diagnosis of Parkinson’s disease versus other progressive movement disorders. Ann Nucl Med. 2016;30:153–62.
Hwang WJ, Yao WJ, Wey SP, Ting G. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson’s disease. J Nucl Med. 2004;45:207–13.
Núñez EGF, Faintuch BL, Teodoro R, Wiecek DP, Martinelli JR, NGd S, Castanheira CE, Filho RSO, Pasqualini R. Influence of colloid particle profile on sentinel lymph node uptake. Nucl Med Biol. 2009;36:741–7.
van der Poel HG, Buckle T, Brouwer OR, Olmos RAV, van Leeuwen FWB. Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol. 2011;60:826–33.
Azad AK, Rajaram MVS, Metz WL, Cope FO, Blue MS, Vera DR, Schlesinger LS. γ-Tilmanocept, a new radiopharmaceutical tracer for cancer sentinel lymph nodes, binds to the mannose receptor (CD206). J Immunol. 2015;195:2019–29.
Baker JL, Pu M, Tokin CA, Hoh CK, Vera DR, Messer K, Wallace AM. Comparison of [99mTc]tilmanocept and filtered [99mTc]sulfur colloid for identification of SLNs in breast cancer patients. Ann Surg Oncol. 2015;22:40–5.
Surasi DS, O’Malley J, Bhambhvani P. 99mTc-tilmanocept: a novel molecular agent for lymphatic mapping and sentinel lymph node localization. J Nucl Med Technol. 2015;43:87–91.
Vera DR, Wallace AM, Hoh CK, Mattrey RF. A synthetic macromolecule for sentinel node detection: 99mTc-DTPA-mannosyl-dextran. J Nucl Med. 2001;42:951–9.
Chen K, Chen X. Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol. 2011;38:70–86.
Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
Wang X, Feng H, Zhao S, Xu J, Wu X, Cui J, Zhang Y, Qin Y, Liu Z, Gao T, Gao Y, Zeng W. SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic. Oncotarget. 2017;8:20476–95.
Adak S, Bhalla R, Vijaya Raj KK, Mandal S, Pickett R, Luthra SK. Radiotracers for SPECT imaging: current scenario and future prospects. Radiochim Acta. 2012;100:95–107.
Belhocine TZ, Blankenberg FG, Kartachova MS, Stitt LW, Vanderheyden J-L, Hoebers FJP, Van de Wiele C. 99mTc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials. Eur J Nucl Med Mol Imaging. 2015;42:2083–97.
Kemerink GJ, Boersma HH, Thimister PW, Hofstra L, Liem I, Pakbiers M-TW, Janssen D, Reutelingsperger CP, Heidendal GA. Biodistribution and dosimetry of 99mTc-BTAP-annexin-V in humans. Eur J Nucl Med. 2001;28:1373–8.
Belhocine T, Steinmetz N, Green A, Rigo P. In vivo imaging of chemotherapy-induced apoptosis in human cancers. Ann NY Acad Sci. 2006;1010:525–9.
Steinmetz N (2004) North American Scientific releases updated observations from European clinical trials of 99mTc-Hynic-annexin. in 51st. In: Annual meeting of the society of nuclear medicine, Philadelphia, PA
Van de Wiele C, Lahorte C, Vermeersch H, Loose D, Mervillie K, Steinmetz ND, Vanderheyden J-L, Cuvelier CA, Slegers G, Dierck RA. Quantitative tumor apoptosis imaging using technetium-99m–HYNIC annexin V single photon emission computed tomography. J Clin Oncol. 2003;21:3483–7.
Vermeersch H, Ham H, Rottey S, Lahorte C, Corsetti F, Dierckx R, Steinmetz N, Van de Wiele C. Intraobserver, interobserver, and day-to-day reproducibility of quantitative 99mTc-HYNIC annexin-V imaging in head and neck carcinoma. Cancer Biother Radiopharm. 2004;19:205–10.
Vermeersch H, Loose D, Lahorte C, Mervillie K, Dierckx R, Steinmetz N, Vanderheyden J-L, Cuvelier C, Slegers G, Van de Wiele C. 99mTc-HYNIC annexin-V imaging of primary head and neck carcinoma. Nucl Med Commun. 2004;25:259–63.
Haas RLM, de Jong D, Valdés Olmos RA, Hoefnagel CA, van Den Heuvel I, Zerp SF, Bartelink H, Verheij M. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Rad Oncol Biol Phys. 2004;59:782–7.
Kartachova M, Haas RLM, Valdés Olmos RA, Hoebers FJP, van Zandwijk N, Verheij M. In vivo imaging of apoptosis by 99mTc-annexin V scintigraphy: visual analysis in relation to treatment response. Radiother Oncol. 2004;72:333–9.
Rottey S, Slegers G, Van Belle S, Goethals I, Van De Wiele C. Sequential 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. J Nucl Med. 2006;47:1813–8.
Rottey S, Loose D, Vakaet L, Lahorte C, Vermeersch H, Van Belle S, Van De Wiele CV. 99mTc-HYNIC annexin-V imaging of tumors and its relationship to response to radiotherapy and/or chemotherapy. Q J Nucl Med Mol Imaging. 2007;51:182–8.
Kartachova M, van Zandwijk N, Burgers S, van Tinteren H, Verheij M, Olmos RAV. Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. J Clin Oncol. 2007;25:2534–9.
Kartachova MS, Olmos RAV, Haas RLM, Hoebers FJR, Herk MV, Verheij M. 99mTc-HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome. Nucl Med Commun. 2008;29:39–44.
Hoebers FJP, Kartachova M, de Bois J, van den Brekel MWM, van Tinteren H, van Herk M, Rasch CRN, Valdés Olmos RA, Verheij M. 99mTc Hynic-rh-annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2008;35:509–18.
Loose D, Vermeersch H, De Vos F, Deron P, Slegers G, Van de Wiele C. Prognostic value of 99mTc-HYNIC annexin-V imaging in squamous cell carcinoma of the head and neck. Eur J Nucl Med Mol Imaging. 2008;35:47–52.
Rottey S, Van Den Bossche B, Slegers G, Van Belle S, Van De Wiele C. Influence of chemotherapy on the biodistribution of [99mTc]hydrazinonicotinamide annexin V in cancer patients. Q J Nucl Med Mol Imaging. 2009;53:127–32.
Kurihara H, Yang DJ, Cristofanilli M, Erwin WD, Yu D-F, Kohanim S, Mendez R, Kim EE. Imaging and dosimetry of 99mTc EC annexin v: preliminary clinical study targeting apoptosis in breast tumors. Appl Radiat Isot. 2008;66:1175–82.
Schaper FL, Reutelingsperger CP. 99mTc-HYNIC-annexin A5 in oncology: evaluating efficacy of anti-cancer therapies. Cancers. 2013;5:550–68.
Cai WB, Rao JH, Gambhir SS, Chen XY. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther. 2006;5:2624–33.
Chen K, Conti PS. Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev. 2010;62:1005–22.
Bozon-Petitprin A, Bacot S, Gauchez AS, Ahmadi M, Bourre JC, Marti-Batlle D, Perret P, Broisat A, Riou LM, Claron M, Boturyn D, Fagret D, Ghezzi C, Vuillez JP. Targeted radionuclide therapy with RAFT-RGD radiolabelled with 90Y or 177Lu in a mouse model of αvβ3-expressing tumours. Eur J Nucl Med Mol Imaging. 2015;42:252–63.
Chen HJ, Niu G, Wu H, Chen XY. Clinical application of radiolabeled RGD peptides for PET imaging of integrin αvβ3. Theranostics. 2016;6:78–92.
Shao G, Gu W, Guo M, Zang S, Fu J, Liu S, Wang F, Wang Z. Clinical study of 99mTc-3P-RGD2 peptide imaging in osteolytic bone metastasis. Oncotarget. 2017;8:75587–96.
O’Connor MK, Morrow MMB, Hunt KN, Boughey JC, Wahner-Roedler DL, Conners AL, Rhodes DJ, Hruska CB. Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer. EJNMMI Res. 2017;7:5.
Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the a avb3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiol. 2010;51:40–6.
Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, Fangberget A, Tangerud Å, Tobin D. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med. 2006;47:1434–9.
Bach-Gansmo T, Bogsrud TV, Skretting A. Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and 99mTc-labelled NC100692. Clin Physiol Funct Imaging. 2008;28:235–9.
Zhu Z, Miao W, Li Q, Dai H, Ma Q, Wang F, Yang A, Jia B, Jing X, Liu S, Shi J, Liu Z, Zhao Z, Wang F, Li F. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med. 2012;53:716–22.
Zhao D, Jin X, Li F, Liang J, Lin Y. Integrin αvβ3 imaging of radioactive iodine–refractory thyroid cancer using 99mTc-3PRGD2. J Nucl Med. 2012;53:1872–7.
Zhang Z, Zhao X, Ding C, Wang J, Zhang J, Wang F. 99mTc-3PRGD2 SPECT/CT imaging for monitoring early response of EGFR-TKIs therapy in patients with advanced-stage lung adenocarcinoma. Cancer Biother Radiopharm. 2016;31:238–45.
Jin X, Liang N, Wang M, Meng Y, Jia B, Shi X, Li S, Luo J, Luo Y, Cui Q, Zheng K, Liu Z, Shi J, Li F, Wang F, Zhu Z. Integrin imaging with 99mTc-3PRGD2 SPECT/CT shows high specificity in the diagnosis of lymph node metastasis from non–small cell lung cancer. Radiology. 2016;281:958–66.
Miao W, Zheng S, Dai H, Wang F, Jin X, Zhu Z, Jia B. Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study. PLoS One. 2014;9:e111221.
Liu L, Song Y, Gao S, Ji TF, Zhang HS, Ji B, Chen B, Jia B, Wang F, Xu ZL, Ma QJ. 99mTc-3PRGD2 scintimammography in palpable and nonpalpable breast lesions. Mol Imaging. 2014;13:28650261.
Dijkgraaf I, Kruijtzer JAW, Liu S, Soede AC, Oyen WJG, Corstens FHM, Liskamp RMJ, Boerman OC. Improved targeting of the αvβ3 integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging. 2007;34:267–73.
Liu Z, Niu G, Shi J, Liu S, Wang F, Liu S, Chen X. 68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin αvβ3 PET imaging. Eur J Nucl Med Mol Imaging. 2009;36:947–57.
Sancey L, Garanger E, Foillard S, Schoehn G, Hurbin A, Albiges-Rizo C, Boturyn D, Souchier C, Grichine A, Dumy P, Coll J-L. Clustering and internalization of integrin αvβ3 with a tetrameric RGD-synthetic peptide. Mol Ther. 2009;17:837–43.
Shi J, Kim Y-S, Chakraborty S, Jia B, Wang F, Liu S. 2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics. Bioconjug Chem. 2009;20:1559–68.
Zhou Y, Kim Y-S, Chakraborty S, Shi J, Gao H, Liu S. 99mTc-Labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin αvβ3 expression. Mol Imaging. 2011;10:7290.2011.00006.
Chen B, Zhao G, Ma Q, Ji B, Ji T, Xin H, Gao S. 99mTc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8:16064–72.
Krenning EP, Bakker WH, Kooij PPM, Breeman WAP, Oei HY, de Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ, Reijs AEM, van Hagen PM, Koper JW, Lamberts SWJ. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992;33:652–8.
Fani M, Nicolas GP, Wild D. Somatostatin receptor antagonists for imaging and therapy. J Nucl Med. 2017;58:61S–6S.
Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med. 2002;32:84–91.
Mikołajczak R, Maecke HR. Radiopharmaceuticals for somatostatin receptor imaging. Nucl Med Rev. 2016;19:126–32.
Reubi JC, Schär J-C, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.
Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P, Dudczak R, Virgolini I. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2005;32:1144–51.
Rodrigues M, Traub-Weidinger T, Li S, Ibi B, Virgolini I. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2006;33:532–40.
Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. 111In- and 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002;32:148–55.
Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Vorbeck F, Bischof C, Leimer M, Dorner G, Kletter K, Niederle B, Scheithauer W, Smith-Jones P. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med. 1998;39:1928–36.
Forrer F, Uusijärvi H, Waldherr C, Cremonesi M, Bernhardt P, Mueller-Brand J, Maecke HR. A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1257–62.
Giovacchini G, Giovannini E, Riondato M, Ciarmiello A. Radiopharmaceuticals for the diagnosis and therapy of neuroendocrine differentiated prostate cancer. Curr Radiopharm. 2017;10:6–15.
Carrasquillo JA, Pandit-Taskar N, Chen CC. Radionuclide therapy of adrenal tumors. J Surg Oncol. 2012;106:632–42.
Carrasquillo JA, Pandit-Taskar N, Chen CC. I-131 metaiodobenzylguanidine therapy of pheochromocytoma and paraganglioma. Semin Nucl Med. 2016;46:203–14.
Cistaro A, Quartuccio N, Caobelli F, Piccardo A, Paratore R, Coppolino P, Sperandeo A, Arnone G, Ficola U. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma. Nucl Med Rev. 2015;18:102–6.
Grünwald F, Ezziddin S. 131I-Metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 2010;40:153–63.
Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics. 2016;36:258–78.
Van Vickle SS, Thompson RC. 123I-MIBG imaging: patient preparation and technologist’s role. J Nucl Med Technol. 2015;43:82–6.
Vöö S, Bucerius J, Mottaghy FM. I-131-MIBG therapies. Methods. 2011;55:238–45.
Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BLF. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147–59.
Case J, Courter S, Van Vickle S, Bateman T. Novel approaches to measuring 123I-labeled mIBG heart-to-mediastinal (H/M) ratios in a high efficiency, small field of view cardiac SPECT system. J Nucl Med. 2015;56:407.
Dimitriu-Leen AC, Scholte AJHA, Jacobson AF. 123I-MIBG SPECT for evaluation of patients with heart failure. J Nucl Med. 2015;56:25S–30S.
Cavina L, van der Born D, Klaren PHM, Feiters MC, Boerman OC, Rutjes FPJT, editors. Design of radioiodinated pharmaceuticals: structural features affecting metabolic stability towards in vivo deiodination. Eur J Org Chem. 2017;2017:3387–414.
Kung HF, Kung M-P, Choi SR. Radiopharmaceuticals for single-photon emission computed tomography brain imaging. Semin Nucl Med. 2003;33:2–13.
Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2013;84:1288–95.
Djang DSW, Janssen MJR, Bohnen N, Booij J, Henderson TA, Herholz K, Minoshima S, Rowe CC, Sabri O, Seibyl J, Van Berckel BNM, Wanner M. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med. 2012;53:154–63.
Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS, Pupi A. European association of nuclear medicine procedure guidelines for brain neurotransmission SPET using I-123-labelled dopamine transporter ligands. Eur J Nucl Med Mol Imaging. 2002;29:BP30–5.
Wu X, Cai H, Ge R, Li L, Jia Z. Recent progress of imaging agents for Parkinson’s disease. Curr Neuropharmacol. 2014;12:551–63.
Innis R, Zoghbi S, Johnson E, Woods S, Al-Tikriti M, Baldwin R, Seibyl J, Malison R, Zubal G, Charney D, Heninger G, Hoffer P. SPECT imaging of the benzodiazepine receptor in non-human primate brain with [123I]Ro 16-0154. Eur J Pharmacol. 1991;193:249–52.
Zoghbi SS, Baldwin RM, Seibyl JP, Al-Tikriti MS, Zea-Ponce Y, Laruelle M, Sybirska EH, Woods SW, Goddard AW, Malison RT, Zimmerman R, Charney DS, Smith EO, Hoffer PB, Innis RB. Pharmacokinetics of the SPECT benzodiazepine receptor radioligand [123I]iomazenil in human and non-human primates. Nucl Med Biol. 1992;19:881–8.
Pinborg LH, Videbaek C, Hasselbalch SG, Sorensen SA, Wagner A, Paulson OB, Knudsen GM. Benzodiazepine receptor quantification in Huntington’s disease with [[123]I]iomazenil and SPECT. J Neurol Neurosurg Psychiatry. 2001;70:657–61.
Verhoeff N, Soares JC, D’Souza CD, Gil R, Degen K, Abi-Dargham A, Zoghbi SS, Fujita M, Rajeevan N, Seibyl JP, Krystal JH, van Dyck CH, Charney DS, Innis RB. [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Res Neuroimaging. 1999;91:163–73.
Bremner JD, Innis RB, White T, Fujita M, Silbersweig D, Goddard AW, Staib L, Stern E, Cappiello A, Woods S, Baldwin R, Charney DS. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry. 2000;47:96–106.
Moriwaki H, Matsumoto M, Hashikawa K, Oku N, Ishida M, Seike Y, Fukuchi K, Hori M, Nishimura T. Iodine-123-iomazenil and iodine-123-iodoamphetamine SPECT in major cerebral artery occlusive disease. J Nucl Med. 1998;39:1348–53.
Hatazawa J, Satoh T, Shimosegawa E, Okudera T, Inugami A, Ogawa T, Fujita H, Noguchi K, Kanno I, Miura S, Murakami M, Iida H, Miura Y, Uemura K. Evaluation of cerebral infarction with iodine 123-iomazenil SPECT. J Nucl Med. 1995;36:2154–61.
Abiko K, Ikoma K, Shiga T, Katoh C, Hirata K, Kuge Y, Kobayashi K, Tamaki N. I-123 iomazenil single photon emission computed tomography for detecting loss of neuronal integrity in patients with traumatic brain injury. EJNMMI Res. 2017;7:28.
Koizumi H, Fujisawa H, Kurokawa T, Suehiro E, Iwanaga H, Nakagawara J, Suzuki M. Recovered neuronal viability revealed by Iodine-123-iomazenil SPECT following traumatic brain injury. J Cereb Blood Flow Metab. 2010;30:1673–81.
Kung HF, Pan S, Kung M-P, Billings J, Kasliwal R, Reilley J, Alavi A. In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. J Nucl Med. 1989;30:88–92.
Heinzel A, Mohammadkhani Shali S, Dafotakis M, Verburg FA, Mottaghy FM, Winz OH. Comparison of automatic versus manual procedures for the quantification of dopamine D2 receptor availability using I-123-IBZM-SPECT. Nucl Med Commun. 2015;36:1120–6.
Hammesfahr S, Antke C, Mamlins E, Beu M, Wojtecki L, Ferrea S, Dinkelbach L, Moldovan AS, Schnitzler A, Müller HW, Südmeyer M. FP-CIT- and IBZM-SPECT in corticobasal syndrome: results from a clinical follow-up study. Neurodegener Dis. 2016;16:342–7.
Långström B, Karimi F, Watanabe Y. Endogenous compounds labeled with radionuclides of short half-life—some perspectives. J Label Compd Radiopharm. 2013;56:251–62.
Woods DH, Baker MI, Keightley JD, Keightley LJ, Makepeace JL, Pearce AK, Woodman AP, Woods MJ, Woods SA, Waters S. Standardisation of 11C. Appl Radiat Isot. 2002;56:327–30.
Miller PW, Kato K, Långström B. Carbon-11, nitrogen-13, and oxygen-15 chemistry: an introduction to chemistry with short-lived radioisotopes. In: Long NJ, Wong W-T, editors. The chemistry of molecular imaging. Hoboken, NJ: Wiley; 2014. p. 79–103.
Allard M, Fouquet E, James D, Szlosek-Pinaud M. State of art in 11C labelled radiotracers synthesis. Curr Med Chem. 2008;15:235–77.
Ermert J, Coenen HH. Methods for 11C- and 18F-labelling of amino acids and derivatives for positron emission tomography imaging. J Label Compd Radiopharm. 2013;56:225–36.
Pekošak A, Filp U, Poot AJ, Windhorst AD. From carbon-11-labeled amino acids to peptides in positron emission tomography: the synthesis and clinical application. Mol Imaging Biol. 2018;20(4):510–32.
Pike VW, Eakins MN, Allan RM, Selwyn AP. Preparation of [1−11C]acetate—an agent for the study of myocardial metabolism by positron emission tomography. Int J Appl Radiat Isot. 1982;33:505–12.
Norenberg JP, Simpson NR, Dunn BB, Kiesewetter DO. Remote synthesis of [11C]acetate. Int J Appl Radiat Isot. 1992;43:943–5.
Mock BH, Brown-Proctor C, Green MA, Steele B, Glick-Wilson BE, Zheng Q-H. An automated SPE-based high-yield synthesis of [11C]acetate and [11C]palmitate: no liquid–liquid extraction, solvent evaporation or distillation required. Nucl Med Biol. 2011;38:1135–42.
Le Helleix S, Dollé F, Kuhnast B. Easy upgrade of the TRACERLab FX C Pro for [11C]carboxylation reactions: application to the routine production of [1-11C]acetate. Appl Radiat Isot. 2013;82:7–11.
McCarron JA, Turton DR, Pike VW, Poole KG. Remotely-controlled production of the 5-HT1A receptor radioligand, carbonyl-11C WAY-100635, via 11C-carboxylation of an immobilized Grignard reagent. J Label Compd Radiopharm. 1996;38:941–53.
Långström B, Lundqvist H. The preparation of 11C-methyl iodide and its use in the synthesis of 11C-methyl-L-methionine. Int J Appl Radiat Isot. 1976;27:357–63.
Holschbach M, Schüller M. A new and simple on-line method for the preparation of n.c.a. [11C]methyl iodide. Appl Radiat Isot. 1993;44:779–80.
Larsen P, Ulin J, Dahlstrøm K, Jensen M. Synthesis of [11C]iodomethane by iodination of [11C]methane. Appl Radiat Isot. 1997;48:153–7.
Link JM, Krohn KA, Clark JC. Production of [11C]CH3I by single pass reaction of [11C]CH4 with I2. Nucl Med Biol. 1997;24:93–7.
Buckley KR, Huser JM, Jivan S, Chun KS, Ruth TJ. 11C-methane production in small volume, high pressure gas targets. Radiochim Acta. 2000;88:201.
Holschbach M, Schüller M. An on-line method for the preparation of n.c.a. [11CH3]trifluoromethanesulfonic acid methyl ester. Appl Radiat Isot. 1993;44:897–8.
Hara T, Yuasa M. Automated synthesis of [11C]choline, a positron-emitting tracer for tumor imaging. Appl Radiat Isot. 1999;50:531–3.
Någren K, Halldin C. Methylation of amide and thiol functions with [11C]methyl triflate, as exemplified by [11C]NMSP, [11C]flumazenil and [11C]methionine. J Label Compd Radiopharm. 1998;41:831–41.
Mathis CA, Wang Y, Holt DP, Huang G-F, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740–54.
Dannals RF, Ravert HT, James Frost J, Wilson AA, Donald Burns H, Wagner HN. Radiosynthesis of an opiate receptor binding radiotracer: [11C]carfentanil. Int J Appl Radiat Isot. 1985;36:303–6.
Langer O, Nagren K, Dolle F, Lundkvist C, Sandell J, Swahn CG, Vaufrey F, Crouzel C, Maziere B, Halldin C. Precursor synthesis and radiolabelling of the dopamine D2 receptor ligand [11C]raclopride from [11C]methyl triflate. J Label Compd Radiopharm. 1999;42:1183–93.
Comar D, Cartron JC, Maziere M, Marazano C. Labelling and metabolism of methionine methyl-11C. Eur J Nucl Med. 1976;1:11–4.
Mitterhauser M, Wadsak W, Krcal A, Schmaljohann J, Eidherr H, Schmid A, Viernstein H, Dudczak R, Kletter K. New aspects on the preparation of [11C]methionine—a simple and fast online approach without preparative HPLC. Appl Radiat Isot. 2005;62:441–5.
Gómez V, Gispert JD, Amador V, Llop J. New method for routine production of L-[methyl-11C]methionine: in loop synthesis. J Label Compd Radiopharm. 2008;51:83–6.
Iwata R, Pascali C, Yuasa M, Yanai K, Takahashi T, Ido T. On-line [11C]methylation using [11C]methyl iodide for the automated preparation of 11C-radiopharmaceuticals. Int J Appl Radiat Isot. 1992;43:1083–8.
Studenov AR, Jivan S, Adam MJ, Ruth TJ, Buckley KR. Studies of the mechanism of the in-loop synthesis of radiopharmaceuticals. Appl Radiat Isot. 2004;61:1195–201.
Watkins GL, Jewett DM, Keith Mulholland G, Kilbourn MR, Toorongian SA. A captive solvent method for rapid N-[11C]methylation of secondary amides: application to the benzodiazepine, 4′-chlorodiazepam (RO5-4864). Int J Appl Radiat Isot. 1988;39:441–4.
Wilson AA, Garcia A, Jin L, Houle S. Radiotracer synthesis from [11C]-iodomethane: a remarkably simple captive solvent method. Nucl Med Biol. 2000;27:529–32.
Shao X, Hoareau R, Runkle AC, Tluczek LJM, Hockley BG, Henderson BD, Scott PJH. Highlighting the versatility of the Tracerlab synthesis modules. Part 2: fully automated production of [11C]-labeled radiopharmaceuticals using a Tracerlab FXC-Pro. J Label Compd Radiopharm. 2011;54:819–38.
Samuelsson L, Långström B. Synthesis of 1-(2′-deoxy-2′-fluoro-beta-D-arabinofuranosyl)-[methyl-11C]thymine ([11C]FMAU) via a Stille cross-coupling reaction with [11C]methyl iodide. J Label Compd Radiopharm. 2003;46:263–72.
Miller PW, Bender D. [11C]carbon disulfide: a versatile reagent for PET radiolabelling. Chem Eur J. 2012;18:433–6.
Roeda D, Crouzel C. [11C]Formaldehyde revisited: considerable concurrent [11C]formic acid formation in the low-temperature conversion of [11C]carbon dioxide into [11C]formaldehyde. Appl Radiat Isot. 2001;54:935–9.
Kato K, Zhang M-R, Suzuki K. Rapid C-carboxylation of nitro[11C]methane for the synthesis of ethyl nitro[2-11C]acetate. Mol BioSyst. 2008;4:53–5.
Långström B, Itsenko O, Rahman O. [11C]Carbon monoxide, a versatile and useful precursor in labelling chemistry for PET-ligand development. J Label Compd Radiopharm. 2007;50:794–810.
Schelbert HR, Phelps ME, Huang SC, Macdonald NS, Hansen H, Kuhl DE. N-13 ammonia as an indicator of myocardial blood-flow. Circulation. 1981;63:1259–72.
Suda M, Onoguchi M, Tomiyama T, Ishihara K, Takahashi N, Sakurai M, Matsumoto K, Kumita S-i. The reproducibility of time-of-flight PET and conventional PET for the quantification of myocardial blood flow and coronary flow reserve with 13N-ammonia. J Nucl Cardiol. 2016;23:457–72.
Cooper AJL. 13N as a tracer for studying glutamate metabolism. Neurochem Int. 2011;59:456–64.
Bormans G, Langendries W, Mortelmans L, Verbruggen A. On-line anion exchange purification of [13N]NH3 produced by 10 MeV proton irradiation of dilute aqueous ethanol. Appl Radiat Isot. 1995;46:83–6.
Statuto M, Galli E, Bertagna F, Migliorati E, Zanella I, Di Lorenzo D, De Agostini A, Rodella C, Apostoli P, Caimi L, Giubbini R, Biasiotto G. The strange case of the [13N]NH3: validation of the production process for human use. Nucl Med Commun. 2016;37:412–21.
Suzuki K, Yoshida Y. Production of [13N]NH3 with ultra-high specific activity. Appl Radiat Isot. 1999;50:497–503.
Wieland B, Bida G, Padgett H, Hendry G, Zippi E, Kabalka G, Morelle J-L, Verbruggen R, Ghyoot M. In-target production of [13N]ammonia via proton irradiation of dilute aqueous ethanol and acetic acid mixtures. Int J Appl Radiat Isot. 1991;42:1095–8.
Berridge MS, Landmeier BJ. In-target production of [13N]ammonia: target design, products, and operating parameters. Appl Radiat Isot. 1993;44:1433–41.
Vaalburg W, Kamphuis JAA, Beerling-van der Molen HD, Reiffers S, Rijskamp A, Woldring MG. An improved method for the cyclotron production of 13N-labelled ammonia. Int J Appl Radiat Isot. 1975;26:316–8.
Baron J-C, Jones T. Oxygen metabolism, oxygen extraction and positron emission tomography: historical perspective and impact on basic and clinical neuroscience. NeuroImage. 2012;61:492–504.
Zhang K, Herzog H, Mauler J, Filss C, Okell TW, Kops ER, Tellmann L, Fischer T, Brocke B, Sturm W, Coenen HH, Shah NJ. Comparison of cerebral blood flow acquired by simultaneous [15O]water positron emission tomography and arterial spin labeling magnetic resonance imaging. J Cereb Blood Flow Metab. 2014;34:1373–80.
Palmer BM, Sajjad M, Rottenberg DA. An automated [15O]H2O production and injection system for PET imaging. Nucl Med Biol. 1995;22:241–9.
Sajjad M, Liow J-S, Moreno-Cantu J. A system for continuous production and infusion of [15O]H2O for PET activation studies. Appl Radiat Isot. 2000;52:205–10.
Berridge MS, Kjellström R. Designs and use of silver [18O]water targets for [18F]fluoride production. Appl Radiat Isot. 1999;50:699–705.
Ferrieri RA, Alexoff DL, Schlyer DJ, Wolf AP. Remote processing, delivery and injection of H2[15O] produced from a N2/H2 gas target using a simple and compact apparatus. Appl Radiat Isot. 1994;45:1149–54.
Mulholland GK, Kilbourn MR, Moskwa JJ. Direct simultaneous production of [15O]water and [13N]ammonia or [18F]fluoride ion by 26 MeV proton irradiation of a double chamber water target. Int J Appl Radiat Isot. 1990;41:1193–9.
Van Naemen J, Monclus M, Damhaut P, Luxen A, Goldman S. Production, automatic delivery and bolus injection of [15O]water for positron emission tomography studies. Nucl Med Biol. 1996;23:413–6.
Park BK, Kitteringham NR. Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications. Drug Metab Rev. 1994;26:605–43.
Gillis EP, Eastman KJ, Hill MD, Donnelly DJ, Meanwell NA. Applications of fluorine in medicinal chemistry. J Med Chem. 2015;58:8315–59.
Coenen HH. Fluorine-18 labeling methods: features and possibilities of basic reactions. In: Schubiger PA, Lehmann L, Friebe M, editors. PET chemistry: the driving force in molecular imaging. Ernst Schering Research Foundation workshop, vol. 62. Berlin: Springer-Verlag; 2007. p. 15–50.
Coenen HH, Ermert J. 18F-labelling innovations and their potential for clinical application. Clin Transl Imaging. 2018;6:169–93.
Ermert J, Coenen HH. No-carrier-added [18F]fluorobenzene derivatives as intermediates for built-up radiosyntheses. Curr Radiopharm. 2010;3:127–60.
Ido T, Wan CN, Casella V, Fowler JS, Wolf AP, Reivich M, Kuhl DE. Labeled 2-deoxy-D-glucose analogs. 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose. J Label Compd Radiopharm. 1978;14:175–83.
Shiue C-Y, Salvadori PA, Wolf AP, Fowler JS, MacGregor RR. A new improved synthesis of 2-deoxy-2-[18F]fluoro-D-glucose from 18F-labeled acetyl hypofluorite. J Nucl Med. 1982;23:899–903.
Firnau G, Chirakal R, Sood S, Garnett S. Aromatic fluorination with xenon difluoride: L-3,4-dihydroxy-6-fluorophenylalanine. Can J Chem. 1980;58:1449–50.
Coenen HH, Franken K, Kling P, Stöcklin G. Direct electrophilic radiofluorination of phenylalanine, tyrosine and dopa. Int J Appl Radiat Isot. 1988;39:1243–50.
Chirakal R, Firnau G, Couse J, Garnett ES. Radiofluorination with 18F-labelled acetyl hypofluorite: [18F]L-6-fluorodopa. Int J Appl Radiat Isot. 1984;35:651–3.
Fowler JS, Shiue CY, Wolf AP, Salvadori PA, MacGregor RR. 18F-labeled acetyl hypofluorite for radiotracer synthesis. J Label Compd Radiopharm. 1982;19:1634–6.
Hiller A, Fischer C, Jordanova A, Patt JT, Steinbach J. Investigations to the synthesis of n.c.a. [18F]FClO3 as electrophilic fluorinating agent. Appl Radiat Isot. 2008;66:152–7.
Adam MJ, Ruth TJ, Grierson JR, Abeysekera B, Pate BD. Routine synthesis of L-[18F]6-fluorodopa with fluorine-18 acetyl hypofluorite. J Nucl Med. 1986;27:1462–6.
de Vries EFJ, Luurtsema G, Brüssermann M, Elsinga PH, Vaalburg W. Fully automated synthesis module for the high yield one-pot preparation of 6-[18F]fluoro-l-DOPA. Appl Radiat Isot. 1999;51:389–94.
Forsback S, Eskola O, Haaparanta M, Bergmann J, Solin O. Electrophilic synthesis of 6-[18F]fluoro-L-DOPA using post-target produced [18F]F2. Radiochim Acta. 2008;96:845–8.
Stenhagen ISR, Kirjavainen AK, Forsback SJ, Jørgensen CG, Robins EG, Luthra SK, Solin O, Gouverneur V. Fluorination of an arylboronic ester using [18F]selectfluor bis(triflate): application to 6-[18F]fluoro-L-DOPA. Chem Commun. 2013;49:1386–8.
Murali D, Flores LG, Roberts AD, Nickles RJ, DeJesus OT. Aromatic l-amino acid decarboxylase (AAAD) inhibitors as carcinoid tumor-imaging agents: synthesis of 18F-labeled α-fluoromethyl-6-fluoro-m-tyrosine (FM-6-FmT). Appl Radiat Isot. 2003;59:237–43.
Coenen HH, Moerlein SM. Regiospecific aromatic fluorodemetallation of group IVb metalloarenes using elemental fluorine or acetyl hypofluorite. J Fluor Chem. 1987;36:63–75.
Teare H, Robins EG, Årstad E, Luthra SK, Gouverneur V. Synthesis and reactivity of [18F]-N-fluorobenzenesulfonimide. Chem Commun. 2007;23:2330–2.
Satyamurthy N, Bida GT, Phelps ME, Barrio JR. N-[18F]fluoro-N-alkylsulfonamides: novel reagents for mild and regioselective radiofluorination. Appl Radiat Isot. 1990;41:733–8.
Oberdorfer F, Hofmann E, Maier-Borst W. Preparation of 18F-labelled N-fluoropyridinium triflate. J Label Compd Radiopharm. 1988;25:999–1005.
Purrington ST, Jones WA. 1-Fluoro-2-pyridone: a useful fluorinating reagent. J Org Chem. 1983;48:761–2.
Teare H, Robins EG, Kirjavainen A, Forsback S, Sandford G, Solin O, Luthra SK, Gouverneur V. Radiosynthesis and evaluation of [18F]selectfluor bis(triflate). Angew Chem Int Ed Engl. 2010;49:6821–4.
Lee E, Kamlet AS, Powers DC, Neumann CN, Boursalian GB, Furuya T, Choi DC, Hooker JM, Ritter T. A fluoride-derived electrophilic late-stage fluorination reagent for PET imaging. Science. 2011;334:639–42.
Zlatopolskiy BD, Zischler J, Urusova EA, Endepols H, Kordys E, Frauendorf H, Mottaghy FM, Neumaier B. A practical one-pot synthesis of positron emission tomography (PET) tracers via nickel-mediated radiofluorination. Chem Open. 2015;4:457–62.
Lee E, Hooker JM, Ritter T. Nickel-mediated oxidative fluorination for PET with aqueous [18F]fluoride. J Am Chem Soc. 2012;134:17456–8.
Richarz R, Krapf P, Zarrad F, Urusova EA, Neumaier B, Zlatopolskiy BD. Neither azeotropic drying, nor base nor other additives: a minimalist approach to 18F-labeling. Org Biomol Chem. 2014;12:8094–9.
Dollé F, Helfenbein J, Hinnen F, Mavel S, Mincheva Z, Saba W, Schollhorn-Peyronneau MA, Valette H, Garreau L, Chalon S, Halldin C, Madelmont JC, Deloye JB, Bottlaender M, Le Gailliard J, Guilloteau D, Emond P. One-step radiosynthesis of [18F]LBT-999: a selective radioligand for the visualization of the dopamine transporter with PET. J Label Compd Radiopharm. 2007;50:716–23.
Mukherjee J, Christian BT, Dunigan KA, Shi BZ, Narayanan TK, Satter M, Mantil J. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse. 2002;46:170–88.
Mukherjee J, Yang Z-Y, Brown T, Lew R, Wernick M, Ouyang X, Yasillo N, Chen C-T, Mintzer R, Cooper M. Preliminary assessment of extrastriatal dopamine d-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl Med Biol. 1999;26:519–27.
Lee SJ, Oh SJ, Moon WY, Choi MS, Kim JS, Chi DY, Moon DH, Ryu JS. New automated synthesis of [18F]FP-CIT with base amount control affording high and stable radiochemical yield: a 1.5-year production report. Nucl Med Biol. 2011;38:593–7.
Gründer G, Siessmeier T, Lange-Asschenfeldt C, Vernaleken I, Buchholz H-G, Stoeter P, Drzezga A, Lüddens H, Rösch F, Bartenstein P. [18F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors. Eur J Nucl Med. 2001;28:1463–70.
Wang HL, Guo XY, Jiang SD, Tang GH. Automated synthesis of [18F]Florbetaben as Alzheimer’s disease imaging agent based on a synthesis module system. Appl Radiat Isot. 2013;71:41–6.
Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235–8.
Bourdier T, Greguric I, Roselt P, Jackson T, Faragalla J, Katsifis A. Fully automated one-pot radiosynthesis of O-(2-[18F]fluoroethyl)-L-tyrosine on the TracerLab FXFN module. Nucl Med Biol. 2011;38:645–51.
Hamacher K, Coenen HH. Efficient routine production of the 18F-labelled amino acid O-(2-[18F]fluoroethyl)-l-tyrosine. Appl Radiat Isot. 2002;57:853–6.
Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med. 1984;25:1212–21.
Römer J, Steinbach J, Kasch H. Studies on the synthesis of 16α-[18F]fluoroestradiol. Appl Radiat Isot. 1996;47:395–9.
Ahmed N, Langlois R, Rodrigue S, Bénard F, van Lier JE. Automated synthesis of 11b-methoxy-4,16a-[16a-18F]difluoroestradiol (4F-M[18F]FES) for estrogen receptor imaging by positron emission tomography. Nucl Med Biol. 2007;34:459–64.
Marchand P, Ouadi A, Pellicioli M, Schuler J, Laquerriere P, Boisson F, Brasse D. Automated and efficient radiosynthesis of [18F]FLT using a low amount of precursor. Nucl Med Biol. 2016;43:520–7.
Been LB, Suurmeijer AJH, Cobben DCP, Jager PL, Hoekstra HJ, Elsinga PH. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging. 2004;31:1659–72.
Grierson JR, Shields AF. Radiosynthesis of 3′-deoxy-3′-[18F]fluorothymidine: [18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol. 2000;27:143–56.
Machulla H-J, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson JR. Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Chem. 2000;243:843–6.
Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ. Imaging proliferation in vivo with F-18 FLT and positron emission tomography. Nat Med. 1998;4:1334–6.
Chang CW, Chou TK, Liu RS, Wang SJ, Lin WJ, Chen CH, Wang HE. A robotic synthesis of [18F]fluoromisonidazole ([18F]FMISO). Appl Radiat Isot. 2007;65:682–6.
Grierson JR, Link JM, Mathis CA, Rasey JS, Krohn KA. A radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med. 1989;30:343–50.
Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012;15:45–55.
Ponde DE, Dence CS, Oyama N, Kim J, Tai Y-C, Laforest R, Siegel BA, Welch MJ. 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging—in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med. 2007;48:420–8.
Zhou D, Lin M, Yasui N, Al-Qahtani MH, Dence CS, Schwarz S, Katzenellenbogen JA. Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-18F-fluoroestradiol (FES), 18F-fluoro furanyl norprogesterone (FFNP), and 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals. J Label Compd Radiopharm. 2014;57:371–7.
Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, Wester HJ, Beck R, McEwan AJB, Wiebe LI, Schwaiger M. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med. 2005;46:106–13.
Turton DR, Betts HM, Dutton D, Perkins AC. Automated radiosynthesis of GMP quality [18F]HX4 for PET imaging of hypoxia. Nucl Med Biol. 2015;42:494–8.
Liu YJ, Zhu L, Plossl K, Choi SR, Qiao HW, Sun XT, Li S, Zha ZH, Kung HF. Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer’s disease. Nucl Med Biol. 2010;37:917–25.
Ding YS, Fowler JS, Gatley SJ, Dewey SL, Wolf AP, Schlyer DJ. Synthesis of high specific activity 6-[18F]fluorodopamine for positron emission tomography studies of sympathetic nervous tissue. J Med Chem. 1991;34:861–3.
Shiue CY, Shiue GG, Mozley PD, Kung MP, Zhuang ZP, Kim HJ, Kung HF. p-[18F]-MPPF: a potential radioligand for PET studies of 5-HT1A receptors in humans. Synapse. 1997;25:147–54.
Martinez G, Vernooij RWM, Padilla PF, Zamora J, Flicker L, Cosp XB. 18F PET with flutemetamol for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017;11:CD012884.
Kilbourn MR, Welch MJ, Dence CS. Carrier-added and no-carrier-added syntheses of [18F]spiroperidol and [18F]haloperidol. Int J Appl Radiat Isot. 1984;35:591–8.
Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med. 1991;32:2266–72.
Preshlock S, Tredwell M, Gouverneur V. 18F-labeling of arenes and heteroarenes for applications in positron emission tomography. Chem Rev. 2016;116:719–66.
Pike VW. Hypervalent aryliodine compounds as precursors for radiofluorination. J Label Compd Radiopharm. 2018;61:196–227.
Ross TL, Ermert J, Hocke C, Coenen HH. Nucleophilic 18F-fluorination of heteroaromatic iodonium salts with no-carrier-added [18F]fluoride. J Am Chem Soc. 2007;129:8018–25.
Zhang MR, Kumata K, Suzuki K. A practical route for synthesizing a PET ligand containing [18F]fluorobenzene using reaction of diphenyliodonium salt with [18F]F−. Tetrahedron Lett. 2007;48:8632–5.
Telu S, Chun J-H, Simeon FG, Lu S, Pike VW. Syntheses of mGluR5 PET radioligands through the radiofluorination of diaryliodonium tosylates. Org Biomol Chem. 2011;9(19):6629–38.
Moon B, Park J, Lee H, Lee B, Kim S. Routine production of [18F]flumazenil from iodonium tosylate using a sample pretreatment method: a 2.5-year production report. Mol Imaging Biol. 2014;16:619–25.
Xu R, Zanotti-Fregonara P, Zoghbi SS, Gladding RL, Woock AE, Innis RB, Pike VW. Synthesis and evaluation in monkey of [18F]4-fluoro-N-methyl-N-(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)benzamide ([18F]FIMX): a promising radioligand for PET imaging of brain metabotropic glutamate receptor 1 (mGluR1). J Med Chem. 2013;56:9146–55.
Jung Y-W, Jang KS, Gu G, Koeppe RA, Sherman PS, Quesada CA, Raffel DM. [18F]Fluoro-hydroxyphenethylguanidines: efficient synthesis and comparison of two structural isomers as radiotracers of cardiac sympathetic innervation. ACS Chem Neurosci. 2017;8:1530–42.
Edwards R, Westwell AD, Daniels S, Wirth T. Convenient synthesis of diaryliodonium salts for the production of [18F]F-DOPA. Eur J Org Chem. 2015;2015:625–30.
Libert LC, Franci X, Plenevaux AR, Ooi T, Maruoka K, Luxen AJ, Lemaire CF. Production at the curie level of no-carrier-added 6-18F-fluoro-L-dopa. J Nucl Med. 2013;54:1154–61.
Cardinale J, Ermert J, Humpert S, Coenen HH. Iodonium ylides for one-step, no-carrier-added radiofluorination of electron rich arenes, exemplified with 4-(([18F]fluorophenoxy)-phenylmethyl) piperidine NET and SERT ligands. RSC Adv. 2014;4:17293–9.
Rotstein BH, Stephenson NA, Vasdev N, Liang SH. Spirocyclic hypervalent iodine(III)-mediated radiofluorination of non-activated and hindered aromatics. Nat Commun. 2014;5:4365.
Ichiishi N, Brooks AF, Topczewski JJ, Rodnick ME, Sanford MS, Scott PJH. Copper-catalyzed [18F]fluorination of (Mesityl)(aryl)iodonium salts. Org Lett. 2014;16:3224–7.
Tredwell M, Preshlock SM, Taylor NJ, Gruber S, Huiban M, Passchier J, Mercier J, Génicot C, Gouverneur V. A general copper-mediated nucleophilic 18F fluorination of arenes. Angew Chem Int Ed Engl. 2014;53:7751–5.
Mossine AV, Brooks AF, Makaravage KJ, Miller JM, Ichiishi N, Sanford MS, Scott PJH. Synthesis of [18F]arenes via the copper-mediated [18F]fluorination of boronic acids. Org Lett. 2015;17:5780–3.
Makaravage KJ, Brooks AF, Mossine AV, Sanford MS, Scott PJH. Copper-mediated radiofluorination of arylstannanes with [18F]KF. Org Lett. 2016;18:5440–3.
Mossine AV, Brooks AF, Ichiishi N, Makaravage KJ, Sanford MS, Scott PJH. Development of customized [18F]fluoride elution techniques for the enhancement of copper-mediated late-stage radiofluorination. Sci Rep. 2017;7:233.
Zarrad F, Zlatopolskiy B, Krapf P, Zischler J, Neumaier B. A practical method for the preparation of 18F-labeled aromatic amino acids from nucleophilic [18F]fluoride and stannyl precursors for electrophilic radiohalogenation. Molecules. 2017;22:2231.
Zischler J, Kolks N, Modemann D, Neumaier B, Zlatopolskiy BD. Alcohol-enhanced Cu-mediated radiofluorination. Chem Eur J. 2017;23:3251–6.
Zlatopolskiy BD, Zischler J, Krapf P, Zarrad F, Urusova EA, Kordys E, Endepols H, Neumaier B. Copper-mediated aromatic radiofluorination revisited: efficient production of PET tracers on a preparative scale. Chem Eur J. 2015;21:5972–9.
Zischler J, Krapf P, Richarz R, Zlatopolskiy BD, Neumaier B. Automated synthesis of 4-[18F]fluoroanisole, [18F]DAA1106 and 4-[18F]FPhe using Cu-mediated radiofluorination under “minimalist” conditions. Appl Radiat Isot. 2016;115:133–7.
Mu L, Fischer CR, Holland JP, Becaud J, Schubiger PA, Schibli R, Ametamey SM, Graham K, Stellfeld T, Dinkelborg LM, Lehmann L. 18F-radiolabeling of aromatic compounds using triarylsulfonium salts. Eur J Org Chem. 2012;2012:889–92.
Chun J-H, Morse CL, Chin FT, Pike VW. No-carrier-added [18F]fluoroarenes from the radiofluorination of diaryl sulfoxides. Chem Commun. 2013;49:2151–3.
Ravert HT, Holt DP, Dannals RF. Synthesis of 2-([18F]fluoro)-3-[(2S)-2-azetidinylmethoxy]pyridine ([18F]2FA). In: Scott PJH, Hockley BG, editors. Radiochemical syntheses. Hoboken, NJ: John Wiley and Sons; 2012.
Fischer S, Hiller A, Smits R, Hoepping A, Funke U, Wenzel B, Cumming P, Sabri O, Steinbach J, Brust P. Radiosynthesis of racemic and enantiomerically pure (−)-[18F]flubatine—a promising PET radiotracer for neuroimaging of α4β2 nicotinic acetylcholine receptors. Appl Radiat Isot. 2013;74:128–36.
Cai H, Yin DZ, Zhang L, Wang YX. The synthesis of a new probe for PET imaging reporter gene HSV1-tk: 2-amino-6-[18F]fluoro-9-(4-hydroxy-3-hydroxymethylbutyl) purine (6-[18F]fluoropenciclovir). J Label Compd Radiopharm. 2006;49:653–61.
Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Leotta K, Eder M, Neels OC, Haberkorn U, Giesel FL, Kopka K. Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J Nucl Med. 2017;58:425–31.
Cardinale J, Martin R, Remde Y, Schäfer M, Hienzsch A, Hübner S, Zerges A-M, Marx H, Hesse R, Weber K, Smits R, Hoepping A, Müller M, Neels O, Kopka K. Procedures for the GMP-compliant production and quality control of [18F]PSMA-1007: a next generation radiofluorinated tracer for the detection of prostate cancer. Pharmaceuticals. 2017;10:77.
Smith GE, Sladen HL, Biagini SCG, Blower PJ. Inorganic approaches for radiolabelling biomolecules with fluorine-18 for imaging with positron emission tomography. Dalton Trans. 2011;40:6196–205.
Burke BP, Clemente GS, Archibald SJ. Boron-18F containing positron emission tomography radiotracers: advances and opportunities. Contrast Media Mol Imaging. 2015;10:96–110.
Keller UAD, Bellac CL, Li Y, Lou YM, Lange PF, Ting R, Harwig C, Kappelhoff R, Dedhar S, Adam MJ, Ruth TJ, Benard F, Perrin DM, Overall CM. Novel matrix metalloproteinase inhibitor [18F]marimastat-aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer. Cancer Res. 2010;70:7562–9.
Li Y, Ting R, Harwig CW, Auf Dem Keller U, Bellac CL, Lange PF, Inkster JAH, Schaffer P, Adam MJ, Ruth TJ, Overall CM, Perrin DM. Towards kit-like 18F-labeling of marimastat, a noncovalent inhibitor drug for in vivo PET imaging cancer associated matrix metalloproteases. Medchemcomm. 2011;2:942–9.
Li Z, Lin T-P, Liu S, Huang C-W, Hudnall TW, Gabbai FP, Conti PS. Rapid aqueous [18F]-labeling of a bodipy dye for positron emission tomography/fluorescence dual modality imaging. Chem Commun. 2011;47:9324–6.
Hendricks JA, Keliher EJ, Wan D, Hilderbrand SA, Weissleder R, Mazitschek R. Synthesis of [18F]BODIPY: bifunctional reporter for hybrid optical/positron emission tomography imaging. Angew Chem. 2012;124:4681–4.
Ortmeyer CP, Haufe G, Schwegmann K, Hermann S, Schafers M, Borgel F, Wunsch B, Wagner S, Hugenberg V. Synthesis and evaluation of a [18F]BODIPY-labeled caspase-inhibitor. Bioorg Med Chem. 2017;25:2167–76.
Schirrmacher R, Bradtmöller G, Schirrmacher E, Thews O, Tillmanns J, Siessmeier T, Buchholz HG, Bartenstein P, Wängler B, Niemeyer CM, Jurkschat K. 18F-labeling of peptides by means of an organosilicon-based fluoride acceptor. Angew Chem Int Ed Engl. 2006;45:6047–50.
Bernard-Gauthier V, Bailey JJ, Liu Z, Wängler B, Wängler C, Jurkschat K, Perrin DM, Schirrmacher R. From unorthodox to established: the current status of 18F-trifluoroborate- and 18F-SiFA-based radiopharmaceuticals in PET nuclear imaging. Bioconjug Chem. 2016;27:267–79.
Lindner S, Michler C, Leidner S, Rensch C, Wängler C, Schirrmacher R, Bartenstein P, Wängler B. Synthesis and in vitro and in vivo evaluation of SiFA-tagged bombesin and RGD peptides as tumor imaging probes for positron emission tomography. Bioconjug Chem. 2014;25:738–49.
Höhne A, Mu L, Honer M, Schubiger PA, Ametamey SM, Graham K, Stellfeld T, Borkowski S, Berndorff D, Klar U, Voigtmann U, Cyr JE, Friebe M, Dinkelborg L, Srinivasan A. Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks. Bioconjug Chem. 2008;19:1871–9.
Chen QS, Meng XJ, McQuade P, Rubins D, Lin SA, Zeng ZZ, Haley H, Miller P, Trotter DG, Low PS. Folate-PEG-NOTA-Al18F: a new folate based radiotracer for PET imaging of folate receptor-positive tumors. Mol Pharm. 2017;14:4353–61.
Al-Momani E, Israel I, Samnick S. Validation of a [Al18F]PSMA-11 preparation for clinical applications. Appl Radiat Isot. 2017;130:102–8.
Wan WX, Guo N, Pan DH, Yu CJ, Weng Y, Luo SN, Ding H, Xu YP, Wang LZ, Lang LX, Xie QG, Yang M, Chen XY. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med. 2013;54:691–8.
Cleeren F, Lecina J, Ahamed M, Raes G, Devoogdt N, Caveliers V, McQuade P, Rubins DJ, Li WP, Verbruggen A, Xavier C, Bormans G. Al18F-labeling of heat-sensitive biomolecules for positron emission tomography imaging. Theranostics. 2017;7:2924–39.
van der Born D, Pees A, Poot AJ, Orru RVA, Windhorst AD, Vugts DJ. Fluorine-18 labelled building blocks for PET tracer synthesis. Chem Soc Rev. 2017;46:4709–73.
Rodnick ME, Brooks AF, Hockley BG, Henderson BD, Scott PJH. A fully-automated one-pot synthesis of [18F]fluoromethylcholine with reduced dimethylaminoethanol contamination via [18F]fluoromethyl tosylate. Appl Radiat Isot. 2013;78:26–32.
Shao X, Hockley BG, Hoareau R, Schnau PL, Scott PJH. Fully automated preparation of [11C]choline and [18F]fluoromethylcholine using TracerLab synthesis modules and facilitated quality control using analytical HPLC. Appl Radiat Isot. 2011;69:403–9.
Zuhayra M, Alfteimi A, Forstner CV, Lützen U, Meller B, Henze E. New approach for the synthesis of [18F]fluoroethyltyrosine for cancer imaging: simple, fast, and high yielding automated synthesis. Bioorg Med Chem. 2009;17:7441–8.
Kim D-Y, Kim H-J, Yu K-H, Min J-J. Synthesis of [18F]-labeled (2-(2-fluoroethoxy)ethyl)tris(4-methoxyphenyl)phosphonium cation as a potential agent for positron emission tomography myocardial imaging. Nucl Med Biol. 2012;39:1093–8.
Tang G, Zeng W, Yu M, Kabalka G. Facile synthesis ofN-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) for protein labeling. J Label Compd Radiopharm. 2008;51:68–71.
Lang L, Eckelman WC. Labeling proteins at high specific activity using N-succinidyl 4-[18F](fluoromethyl) benzoate. Appl Radiat Isot. 1997;48:169–73.
Marik J, Sutcliffe JL. Fully automated preparation of n.c.a. 4-[18F]fluorobenzoic acid and N-succinimidyl 4-[18F]fluorobenzoate using a Siemens/CTI chemistry process control unit (CPCU). Appl Radiat Isot. 2007;65:199–203.
Basuli F, Zhang X, Woodroofe CC, Jagoda EM, Choyke PL, Swenson RE. Fast indirect fluorine-18 labeling of protein/peptide using the useful 6-fluoronicotinic acid-2,3,5,6-tetrafluorophenyl prosthetic group: a method comparable to direct fluorination. J Label Compd Radiopharm. 2017;60:168–75.
Olberg DE, Arukwe JM, Grace D, Hjelstuen OK, Solbakken M, Kindberg GM, Cuthbertson A. One step radiosynthesis of 6-[18F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester ([18F]F-Py-TFP): a new prosthetic group for efficient labeling of biomolecules with fluorine-18. J Med Chem. 2010;53:1732–40.
Hedberg E, Langström B. Synthesis of 4-([18F]fluoromethyl)phenyl isothiocyanate and its use in labelling oligonucleotides. Acta Chem Scand. 1997;51:1236–40.
Downer JB, McCarthy TJ, Edwards WB, Anderson CJ, Welch MJ. Reactivity of p-[18F]fluorophenacyl bromide for radiolabeling of proteins and peptides. Appl Radiat Isot. 1997;48:907–16.
Cai W, Zhang X, Wu Y, Chen X. A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido) ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of αvβ3 integrin expression. J Nucl Med. 2006;47:1172–80.
de Bruin B, Kuhnast B, Hinnen F, Yaouancq L, Amessou M, Johannes L, Samson A, Boisgard R, Tavitian B, Dolle F. 1-3-(2-[18F]fluoropyridin-3-yloxy)propyl pyrrole-2,5-dione: design, synthesis, and radiosynthesis of a new [18F]fluoropyridine-based maleimide reagent for the labeling of peptides and proteins. Bioconjug Chem. 2005;16:406–20.
Berndt M, Pietzsch J, Wuest F. Labeling of low-density lipoproteins using the 18F-labeled thiol-reactive reagent N-[6-(4-[18]fluorobenzylidene)aminooxyhexyl]maleimide. Nucl Med Biol. 2007;34:5–15.
Speranza A, Ortosecco G, Castaldi E, Nardelli A, Pace L, Salvatore M. Fully automated synthesis procedure of 4-[18F]fluorobenzaldehyde by commercial synthesizer: amino-oxi peptide labelling prosthetic group. Appl Radiat Isot. 2009;67:1664–9.
Kuhnast B, Dollé F. The challenge of labeling macromolecules with fluorine-18: three decades of research. Curr Radiopharm. 2010;3:174–201.
Maschauer S, Heilmann M, Wängler C, Schirrmacher R, Prante O. Radiosynthesis and preclinical evaluation of 18F-fluoroglycosylated octreotate for somatostatin receptor imaging. Bioconjug Chem. 2016;27:2707–14.
Choi JY, Lee BC. Click reaction: an applicable radiolabeling method for molecular imaging. Nucl Med Mol Imaging. 2015;49:258–67.
Meyer J-P, Adumeau P, Lewis JS, Zeglis BM. Click chemistry and radiochemistry: the first 10 years. Bioconjug Chem. 2016;27:2791–807.
Mamat C, Gott M, Steinbach J. Recent progress using the Staudinger ligation for radiolabeling applications. J Label Compd Radiopharm. 2018;61:165–78.
Campbell-Verduyn LS, Mirfeizi L, Schoonen AK, Dierckx RA, Elsinga PH, Feringa BL. Strain-promoted copper-free “click” chemistry for 18F radiolabeling of bombesin. Angew Chem Int Ed Engl. 2011;50:11117–20.
Agard NJ, Prescher JA, Bertozzi CR. A strain-promoted 3+2 azide-alkyne cycloaddition for covalent modification of blomolecules in living systems. J Am Chem Soc. 2004;126:15046–7.
Zeng DX, Zeglis BM, Lewis JS, Anderson CJ. The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals. J Nucl Med. 2013;54:829–32.
Blackman ML, Royzen M, Fox JM. Tetrazine ligation: fast bioconjugation based on inverse-electron-demand Diels-Alder reactivity. J Am Chem Soc. 2008;130:13518.
Selvaraj R, Liu SL, Hassink M, Huang CW, Yap LP, Park R, Fox JM, Li ZB, Conti PS. Tetrazine-trans-cyclooctene ligation for the rapid construction of integrin αvβ3 targeted PET tracer based on a cyclic RGD peptide. Bioorg Med Chem Lett. 2011;21:5011–4.
Liu SL, Hassink M, Selvaraj R, Yap LP, Park R, Wang H, Chen XY, Fox JM, Li ZB, Conti PS. Efficient 18F labeling of cysteine-containing peptides and proteins using tetrazine-trans-cyclooctene ligation. Mol Imaging. 2013;12:121–8.
Reiner T, Keliher EJ, Earley S, Marinelli B, Weissleder R. Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method. Angew Chem Int Ed Engl. 2011;50:1922–5.
Keinanen O, Fung K, Pourat J, Jallinoja V, Vivier D, Pillarsetty NK, Airaksinen AJ, Lewis JS, Zeglis BM, Sarparanta M. Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models. EJNMMI Res. 2017;7(1):95.
Gao Z, Gouverneur V, Davis BG. Enhanced aqueous Suzuki–Miyaura coupling allows site-specific polypeptide 18F-labeling. J Am Chem Soc. 2013;135:13612–5.
Way JD, Wang M, Hamann I, Wuest M, Wuest F. Synthesis and evaluation of 2-amino-5-(4-[18F]fluorophenyl)pent-4-ynoic acid ([18F]FPhPA): a novel 18F-labeled amino acid for oncologic PET imaging. Nucl Med Biol. 2014;41:660–9.
Wüst FR, Kniess T. Synthesis of 4-[18F]fluoroiodobenzene and its application in Sonogashira cross-coupling reactions. J Label Compd Radiopharm. 2003;46:699–713.
Wüst FR, Höhne A, Metz P. Synthesis of 18F-labelled cyclooxygenase-2 (COX-2) inhibitors via Stille reaction with 4-[18F]fluoroiodobenzene as radiotracers for positron emission tomography (PET). Org Biomol Chem. 2005;3:503–7.
Qaim SM. Development of novel positron emitters for medical applications: nuclear and radiochemical aspects. Radiochim Acta. 2011;99:611–25.
Cascini GL, Niccoli Asabella A, Notaristefano A, Restuccia A, Ferrari C, Rubini D, Altini C, Rubini G. 124Iodine: a longer-life positron emitter isotope – new opportunities in molecular imaging. Biomed Res Int. 2014;2014:672094.
Koehler L, Gagnon K, McQuarrie S, Wuest F. Iodine-124: a promising positron emitter for organic PET chemistry. Molecules. 2010;15:2686–718.
Langen KJ, Coenen HH, Roosen N, Kling P, Muzik O, Herzog H, Kuwert T, Stöcklin G, Feinendegen LE. SPECT studies of brain tumors with L-3-[123I] iodo-α-methyl tyrosine: comparison with PET, 124IMT and first clinical results. J Nucl Med. 1990;31:281–6.
Qaim SM, Hohn A, Bastian T, El-Azoney KM, Blessing G, Spellerberg S, Scholten B, Coenen HH. Some optimisation studies relevant to the production of high-purity 124I and 124I at a small-sized cyclotron. Appl Radiat Isot. 2003;58:69–78.
Moroz MA, Serganova I, Zanzonico P, Ageyeva L, Beresten T, Dyomina E, Burnazi E, Finn RD, Doubrovin M, Blasberg RG. Imaging hNET reporter gene expression with 124I-MIBG. J Nucl Med. 2007;48:827–36.
Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn R, Humm J, Larson S, Sadelain M, Blasberg R, Tjuvajev JG. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A. 2001;98:9300–5.
Wadsak W, Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol. 2010;73:461–9.
Post RL, Jolly PC. The linkage of sodium, potassium, and ammonium active transport across the human erythrocyte membrane. Biochim Biophys Acta. 1957;25:118–28.
Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med. 1996;37:1701–12.
Sciacca RR, Akinboboye O, Ling Chou R, Epstein S, Bergmann SR. Measurement of myocardial blood flow with PET using 1-11C-acetate. J Nucl Med. 2001;42:63–70.
Magata Y, Temma T, Iida H, Ogawa M, Mukai T, Iida Y, Morimoto T, Konishi J, Saji H. Development of injectable O-15 oxygen and estimation of rat OEF. J Cereb Blood Flow Metab. 2003;23:671–6.
Yamauchi H, Higashi T, Kagawa S, Nishii R, Kudo T, Sugimoto K, Okazawa H, Fukuyama H. Is misery perfusion still a predictor of stroke in symptomatic major cerebral artery disease? Brain. 2012;135:2515–26.
Holland JP, Cumming P, Vasdev N. PET radiopharmaceuticals for probing enzymes in the brain. Am J Nucl Med Mol Imaging. 2013;3:194–216.
Rempel BP, Price EW, Phenix CP. Molecular imaging of hydrolytic enzymes using PET and SPECT. Mol Imaging. 2017;16:1536012117717852.
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.
Sols A, Crane RK. Substrate specificity of brain hexokinase. J Biol Chem. 1954;210:581–95.
Brown RS, Wahl RL. Over expression of glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer. 1993;72:2979–85.
DeGrado TR, Wang SY, Holden JE, Nickles RJ, Taylor M, Stone CK. Synthesis and preliminary evaluation of 18F-labeled 4-thia palmitate as a PET tracer of myocardial fatty acid oxidation. Nucl Med Biol. 2000;27:221–31.
Noll C, Carpentier AC. Dietary fatty acid metabolism in prediabetes. Curr Opin Lipidol. 2017;28:1–10.
Takala TO, Nuutila P, Pulkki K, Oikonen V, Gronroos T, Savunen T, Vahasilta T, Luotolahti M, Kallajoki M, Bergman J, Forsback S, Knuuti J. 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid as a tracer of free fatty acid uptake and oxidation in myocardium and skeletal muscle. Eur J Nucl Med Mol Imaging. 2002;29:1617–22.
Clary GL, Tsai C-F, Guynn RW. Substrate specificity of choline kinase. Arch Biochem Biophys. 1987;254:214–21.
Awwad HM, Geisel J, Obeid R. The role of choline in prostate cancer. Clin Biochem. 2012;45:1548–53.
Calabria F, Gallo G, Schillaci O, Cascini GL. Bio-distribution, imaging protocols and diagnostic accuracy of PET with tracers of lipogenesis in imaging prostate cancer: a comparison between 11C-choline, 18F-fluoroethylcholine and 18F-methylcholine. Curr Pharm Des. 2015;21:4738–47.
DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, Reiman R, Price DT, Coleman RE. Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805–14.
Hara T. 18F-Fluorocholine: a new oncologic PET tracer. J Nucl Med. 2001;42:1815–7.
Oprea-Lager DE, van Kanten MP, van Moorselaar RJA, van den Eertwegh AJM, van de Ven PM, Bijnsdorp IV, Hoekstra OS, Geldof AA. [18F]Fluoromethylcholine as a chemotherapy response read-out in prostate cancer cells. Mol Imaging Biol. 2015;17:319–27.
Hodolič M. Imaging of prostate cancer using 18F-choline PET/computed tomography. PET Clin. 2017;12:173–84.
Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med. 1962;3:332–4.
Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68–78.
Shields AF, Grierson JR, Kozawa SM, Zheng M. Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol. 1996;23:17–22.
McKinley ET, Ayers GD, Smith RA, Saleh SA, Zhao P, Washington MK, Coffey RJ, Manning HC. Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS One. 2013;8:e58938.
Schelhaas S, Heinzmann K, Bollineni VR, Kramer GM, Liu Y, Waterton JC, Aboagye EO, Shields AF, Soloviev D, Jacobs AH. Preclinical applications of 3′-deoxy-3′-[18F]fluoro-thymidine in oncology – a systematic review. Theranostics. 2017;7:40–50.
Alauddin MM. Nucleoside-based probes for imaging tumor proliferation using positron emission tomography. J Label Compd Radiopharm. 2013;56:237–43.
Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49:129S–48S.
Bell C, Dowson N, Fay M, Thomas P, Puttick S, Gal Y, Rose S. Hypoxia imaging in gliomas with 18F-fluoromisonidazole PET: toward clinical translation. Semin Nucl Med. 2015;45:136–50.
Wuest M, Wuest F. Positron emission tomography radiotracers for imaging hypoxia. J Label Compd Radiopharm. 2013;56:244–50.
Grönroos T, Eskola O, Lehtiö K, Minn H, Marjamäki P, Bergman J, Haaparanta M, Forsback S, Solin O. Pharmacokinetics of [18F]FETNIM: a potential hypoxia marker for PET. J Nucl Med. 2001;42:1397–404.
Hayashi K, Furutsuka K, Takei M, Muto M, Nakao R, Aki H, Suzuki K, Fukumura T. High-yield automated synthesis of [18F]fluoroazomycin arabinoside ([18F]FAZA) for hypoxia-specific tumor imaging. Appl Radiat Isot. 2011;69:1007–13.
Reischl G, Ehrlichmann W, Bieg C, Solbach C, Kumar P, Wiebe LI, Machulla HJ. Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation. Appl Radiat Isot. 2005;62:897–901.
Kaneta T, Takai Y, Iwata R, Hakamatsuka T, Yasuda H, Nakayama K, Ishikawa Y, Watanuki S, Furumoto S, Funaki Y, Nakata E, Jingu K, Tsujitani M, Ito M, Fukuda H, Takahashi S, Yamada S. Initial evaluation of dynamic human imaging using 18F-FRP170 as a new PET tracer for imaging hypoxia. Ann Nucl Med. 2007;21:101–7.
Eskola O, Grönroos TJ, Forsback S, Tuomela J, Komar G, Bergman J, Härkönen P, Haaparanta M, Minn H, Solin O. Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [18F]EF5. Mol Imaging Biol. 2012;14:205–12.
Silvoniemi A, Suilamo S, Laitinen T, Forsback S, Löyttyniemi E, Vaittinen S, Saunavaara V, Solin O, Grönroos TJ, Minn H. Repeatability of tumour hypoxia imaging using [18F]EF5 PET/CT in head and neck cancer. Eur J Nucl Med Mol Imaging. 2018;45:161–9.
Brosnan JT, Brosnan ME. The sulfur-containing amino acids: an overview. J Nutr. 2006;136:1636S–40S.
Huang C, McConathy J. Fluorine-18 labeled amino acids for oncologic imaging with positron emission tomography. Curr Top Med Chem. 2013;13:871–91.
Jager PL, Vaalburg W, Pruim J, de Vries EGE, Langen K-J, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432–45.
Gulyás B, Halldin C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging. 2012;56:173–90.
Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, Stöcklin G. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205–12.
Langen K-J, Galldiks N, Hattingen E, Shah NJ. Advances in neuro-oncology imaging. Nat Rev Neurol. 2017;13:279–89.
Langen K-J, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, Coenen HH, Pauleit D. O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006;33:287–94.
Geisler S, Ermert J, Stoffels G, Willuweit A, Galldiks N, Filss CP, Shah NJ, Coenen HH, Langen KJ. Isomers of 4-[18F]fluoroproline: radiosynthesis, biological evaluation and results in humans using PET. Curr Radiopharm. 2014;7:123–32.
Goodman MM, Yu W, Jarkas N. Synthesis and biological properties of radiohalogenated α,α-disubstituted amino acids for PET and SPECT imaging of amino acid transporters (AATs). J Label Compd Radiopharm. 2018;61:272–90.
Shoup TM, Olson J, Hoffman JM, Votaw J, Eshima D, Eshima L, Camp VM, Stabin M, Votaw D, Goodman MM. Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med. 1999;40:331–8.
Wallitt KL, Khan SR, Dubash S, Tam HH, Khan S, Barwick TD. Clinical PET imaging in prostate cancer. Radiographics. 2017;37:1512–36.
Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat Rev Neurol. 2014;10:708–22.
Lussey-Lepoutre C, Hindié E, Montravers F, Detour J, Ribeiro MJS, Taïeb D, Imperiale A. The current role of 18F-FDOPA PET for neuroendocrine tumor imaging. Med Nucl. 2016;40:20–30.
Inoue T, Shibasaki T, Oriuchi N, Aoyagi K, Tomiyoshi K, Amano S, Mikuni M, Itsurou I, Aoki J, Endo K. 18F α-methyl tyrosine PET studies in patients with brain tumors. J Nucl Med. 1999;40:399–405.
Wienhard K, Herholz K, Coenen HH, Rudolf J, Kling P, Stöcklin G, Heiss W-D. Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. J Nucl Med. 1991;32:1338–46.
Wahl LM, Chen JJ, Thompson M, Chirakal R, Nahmias C. The time course of metabolites in human plasma after 6-[18F]fluoro-L-m-tyrosine administration. Eur J Nucl Med. 1999;26:1407–12.
Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46:5276–81.
Haberkorn U, Oberdorfer F, Gebert J, Morr I, Haack K, Weber K, Lindauer M, vanKaick G, Schackert HK. Monitoring gene therapy with cytosine deaminase: in vitro studies using tritiated-5-fluorocytosine. J Nucl Med. 1996;37:87–94.
Alrabiah FA, Sacks SL. New antiherpesvirus agents – their targets and therapeutic potential. Drugs. 1996;52:17–32.
Gambhir SS, Barrio JR, Herschman HR, Phelps ME. Imaging gene expression: principles and assays. J Nucl Cardiol. 1999;6:219–33.
Yaghoubi SS, Campbell DO, Radu CG, Czernin J. Positron emission tomography reporter genes and reporter probes: gene and cell therapy applications. Theranostics. 2012;2:374–91.
Ray P, Bauer E, Lyer M, Barrio JR, Satyamurthy N, Phelps ME, Herschman HR, Gambhir SS. Monitoring gene therapy with reporter gene imaging. Semin Nucl Med. 2001;31:312–20.
Tjuvajev JG, Avril N, Oku T, Sasajima T, Miyagawa T, Joshi R, Safer M, Beattie B, DiResta G, Daghighian F, Augensen F, Koutcher J, Zweit J, Humm J, Larson SM, Finn R, Blasberg R. Imaging Herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 1998;58:4333–41.
Alauddin MM, Conti PS. Synthesis and preliminary evaluation of 9-(4-[18F]-fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. Nucl Med Biol. 1998;25:175–80.
Iyer M, Barrio JR, Namavari M, Bauer E, Satyamurthy N, Nguyen K, Toyokuni T, Phelps ME, Herschman HR, Gambhir SS. 8-[18F]fluoropenciclovir: an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using PET. J Nucl Med. 2001;42:96–105.
Alauddin MM, Gelovani JG. Radiolabeled nucleoside analogues for PET imaging of HSV1-tk gene expression. Curr Top Med Chem. 2010;10:1617–32.
Mathis CA, Lopresti BJ, Ikonomovic MD, Klunk WE. Small-molecule PET tracers for Imaging Proteinopathies. Semin Nucl Med. 2017;47:553–75.
Spencer B, Rockenstein E, Crews L, Marr R, Masliah E. Novel strategies for Alzheimer’s disease treatment. Expert Opin Biol Ther. 2007;7:1853–67.
Trojanowski JQ, Shin RW, Schmidt ML, Lee VMY. Relationship between plaques, tangles, and dystrophic processes in Alzheimer’s disease. Neurobiol Aging. 1995;16:335–40.
George N, Gean E, Nandi A, Brašić JR, Wong DF. Radiotracers used to image the brains of patients with Alzheimer’s disease imaging of the human brain in health and disease. Boston, MA: Academic; 2014. p. 407–16.
Oukoloff K, Cieslikiewicz-Bouet M, Chao S, Bran-quinho ED, Bouteiller C, Jean L, Renard PY. PET and SPECT radiotracers for Alzheimer’s disease. Curr Med Chem. 2015;22:3278–304.
Villemagne VL, Furumoto S, Fodero-Tavoletti M, Harada R, Mulligan RS, Kudo Y, Masters CL, Yanai K, Rowe CC, Okamura N. The challenges of tau imaging. Future Neurol. 2012;7:409–21.
Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole GM, Small GW, Huang SC, Barrio JR. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer’s disease. J Neurosci. 2001;21:Article no. RC189.
Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang S-C. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24–35.
Klunk WE, Engler H, Nordberg A, Wang YM, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306–19.
Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y. Diagnostic accuracy of 18F-FDG and 11C-PIB-PET for prediction of short-term conversion to Alzheimer’s disease in subjects with mild cognitive impairment. Int J Clin Pract. 2012;66:185–98.
Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL. Imaging of amyloid b in Alzheimer’s disease with 18F-BAY94-9172 a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129–35.
Martinez G, Vernooij RWM, Padilla PF, Zamora J, Cosp XB, Flicker L. 18F PET with florbetapir for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017;11:CD012216.
Martinez G, Vernooij RWM, Padilla PF, Zamora J, Flicker L, Cosp XB. 18F PET with florbetaben for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017;11:CD012883.
Cselényi Z, Jönhagen ME, Forsberg A, Halldin C, Julin P, Schou M, Johnström P, Varnäs K, Svensson S, Farde L. Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J Nucl Med. 2012;53:415–24.
Hostetler ED, Sanabria-Bohorquez S, Fan H, Zeng ZZ, Gammage L, Miller P, O’Malley S, Connolly B, Mulhearn J, Harrison ST, Wolkenberg SE, Barrow JC, Williams DL, Hargreaves RJ, Sur C, Cook JJ. [18F]Fluoroazabenzoxazoles as potential amyloid plaque PET tracers: synthesis and in vivo evaluation in rhesus monkey. Nucl Med Biol. 2011;38:1193–203.
Ariza M, Kolb HC, Moechars D, Rombouts F, Andrés JI. Tau positron emission tomography (PET) imaging: past, present, and future. J Med Chem. 2015;58:4365–82.
Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, Cao DN, Rigopoulos A, Cartwright GA, O’Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain. 2011;134:1089–100.
Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, Mulligan RS, Villemagne VL, Akatsu H, Yamamoto T, Arai H, Iwata R, Yanai K, Kudo Y. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420–7.
Hashimoto H, Kawamura K, Igarashi N, Takei M, Fujishiro T, Aihara Y, Shiomi S, Muto M, Ito T, Furutsuka K, Yamasaki T, Yui JJ, Xie L, Ono M, Hatori A, Nemoto K, Suhara T, Higuchi M, Zhang MR. Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J Nucl Med. 2014;55:1532–8.
Shidahara M, Watabe H, Tashiro M, Okamura N, Furumoto S, Watanuki S, Furukawa K, Arakawa Y, Funaki Y, Iwata R, Gonda K, Kudo Y, Arai H, Ishiwata K, Yanai K. Quantitative kinetic analysis of PET amyloid imaging agents [11C]BF227 and [18F]FACT in human brain. Nucl Med Biol. 2015;42:734–44.
Wooten DW, Guehl NJ, Verwer EE, Shoup TM, Yokell DL, Zubcevik N, Vasdev N, Zafonte RD, Johnson KA, Fakhri GE, Normandin MD. Pharmacokinetic evaluation of the tau PET radiotracer 18F-T807 (18F-AV-1451) in human subjects. J Nucl Med. 2017;58:484–91.
Declercq L, Celen S, Lecina J, Ahamed M, Tousseyn T, Moechars D, Alcazar J, Ariza M, Fierens K, Bottelbergs A, Mariën J, Vandenberghe R, Andres IJ, Van Laere K, Verbruggen A, Bormans G. Comparison of new tau PET-tracer candidates with [18F]T808 and [18F]T807. Mol Imaging. 2016;15:1–15.
Bredesen DE. Genetic control of neural cell apoptosis. Perspect Dev Neurobiol. 1996;3:101–9.
Faust A, Hermann S, Wagner S, Haufe G, Schober O, Schäfers M, Kopka K. Molecular imaging of apoptosis in vivo with scintigraphic and optical biomarkers – a status report. Anti Cancer Agents Med Chem. 2009;9:968–85.
Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495–516.
Elmenhorst D, Bier D, Holschbach M, Bauer A. Imaging of adenosine receptors PET and SPECT of neurobiological systems. New York, NY: Springer; 2014. p. 181–98.
Boschi S, Lodi F, Boschi L, Nanni C, Chondrogiannis S, Colletti PM, Rubello D, Fanti S. 11C-meta-hydroxyephedrine a promising PET radiopharmaceutical for imaging the sympathetic nervous system. Clin Nucl Med. 2015;40:E96–E103.
Andersson JD, Halldin C. PET radioligands targeting the brain GABAA/benzodiazepine receptor complex. J Label Compd Radiopharm. 2013;56:196–206.
Ahamed M, Verbruggen A, Bormans G. Synthetic strategies for radioligands for in vivo imaging of brain cannabinoid type-1 receptors. J Label Compd Radiopharm. 2013;56:207–14.
Minn H, Kauhanen S, Seppanen M, Nuutila P. 18F-FDOPA: a multiple-target molecule. J Nucl Med. 2009;50:1915–8.
Becker G, Bahri MA, Michel A, Hustadt F, Garraux G, Luxen A, Lemaire C, Plenevaux A. Comparative assessment of 6-[18F]fluoro-L-m-tyrosine and 6-[18F]fluoro-L-dopa to evaluate dopaminergic presynaptic integrity in a Parkinson’s disease rat model. J Neurochem. 2017;141:626–35.
Prante O, Maschauer S, Banerjee A. Radioligands for the dopamine receptor subtypes. J Label Compd Radiopharm. 2013;56:130–48.
Funke U, Vugts DJ, Janssen B, Spaans A, Kruijer PS, Lammertsma AA, Perk LR, Windhorst AD. 11C-labeled and 18F-labeled PET ligands for subtype-specific imaging of histamine receptors in the brain. J Label Compd Radiopharm. 2013;56:120–9.
Mu L, Schubiger PA, Ametamey SM. Radioligands for the PET imaging of metabotropic glutamate receptor subtype 5 (mGluR5). Curr Top Med Chem. 2010;10:1558–68.
Sobrio F. Radiosynthesis of carbon-11 and fluorine-18 labelled radiotracers to image the ionotropic and metabotropic glutamate receptors. J Label Compd Radiopharm. 2013;56:180–6.
Sephton SM. Positron emission tomography of metabotropic glutamate receptors. In: Parrot S, Denoroy L, editors. Biochemical approaches for glutamatergic neurotransmission. New York, NY: Springer; 2018. p. 51–82.
Horti AG, Kuwabara H, Holt DP, Dannals RF, Wong DF. Recent PET radioligands with optimal brain kinetics for imaging nicotinic acetylcholine receptors. J Label Compd Radiopharm. 2013;56:159–66.
Sabri O, Meyer PM, Gräf S, Hesse S, Wilke S, Becker G-A, Rullmann M, Patt M, Luthardt J, Wagenknecht G, Hoepping A, Smits R, Franke A, Sattler B, Tiepolt S, Fischer S, Deuther-Conrad W, Hegerl U, Barthel H, Schönknecht P, Brust P. Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer’s dementia. Brain. 2018;141:1840–54.
Pike VW. Considerations in the development of reversibly binding PET radioligands for brain imaging. Curr Med Chem. 2016;23:1818–69.
McGinnity CJ, Hammers A, Riaño Barros DA, Luthra SK, Jones PA, Trigg W, Micallef C, Symms MR, Brooks DJ, Koepp MJ, Duncan JS. Initial evaluation of 18F-GE-179, a putative PET tracer for activated N-methyl d-aspartate receptors. J Nucl Med. 2014;55:423–30.
Lohith TG, Zoghbi SS, Morse CL, Araneta MDF, Barth VN, Goebl NA, Tauscher JT, Pike VW, Innis RB, Fujita M. Retest imaging of [11C]NOP-1A binding to nociceptin/orphanin FQ peptide (NOP) receptors in the brain of healthy humans. NeuroImage. 2014;87:89–95.
Dannals RF. Positron emission tomography radioligands for the opioid system. J Label Compd Radiopharm. 2013;56:187–95.
Zimmer L, Le Bars D. Current status of positron emission tomography radiotracers for serotonin receptors in humans. J Label Compd Radiopharm. 2013;56:105–13.
Banister SD, Manoli M, Kassiou M. The development of radiotracers for imaging sigma (σ) receptors in the central nervous system (CNS) using positron emission tomography (PET). J Label Compd Radiopharm. 2013;56:215–24.
Riss PJ, Stockhofe K, Roesch F. Tropane-derived 11C-labelled and 18F-labelled DAT ligands. J Label Compd Radiopharm. 2013;56:149–58.
Passchier J, Gunn RN, Van Waarde A. Imaging type 1 glycine transporters in the CNS using positron emission tomography. In: de Vries EFJ, Luiten PGM, Otte A, editors. PET and SPECT of neurobiological systems. New York, NY: Springer; 2014. p. 321–30.
Takano A, Gulyás B, Varrone A, Halldin C. Comparative evaluations of norepinephrine transporter radioligands with reference tissue models in rhesus monkeys: (S,S)-[18F]FMeNER-D2 and (S,S)-[11C]MeNER. Eur J Nucl Med Mol Imaging. 2009;36:1885.
Kilbourn MR. Small molecule PET tracers for transporter imaging. Semin Nucl Med. 2017;47:536–52.
Stehouwer JS, Goodman MM. 11C and 18F PET radioligands for the serotonin transporter (SERT). J Label Compd Radiopharm. 2013;56:114–9.
Kilbourn MR. Radioligands for imaging vesicular monoamine transporters. In: Dierckx RAJO, et al., editors. PET and SPECT of neurobiological systems. Berlin: Springer; 2014. p. 765–90.
Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bedard MA. Quantification of brain cholinergic denervation in Alzheimer’s disease using PET imaging with [18F]-FEOBV. Mol Psychiatry. 2017;22:1531–8.
Damont A, Roeda D, Dollé F. The potential of carbon-11 and fluorine-18 chemistry: illustration through the development of positron emission tomography radioligands targeting the translocator protein 18 kDa. J Label Compd Radiopharm. 2013;56:96–104.
Fan Z, Calsolaro V, Atkinson RA, Femminella GD, Waldman A, Buckley C, Trigg W, Brooks DJ, Hinz R, Edison P. Flutriciclamide (18F-GE180) PET: first-in-human PET study of novel third-generation in vivo marker of human translocator protein. J Nucl Med. 2016;57:1753–9.
Ghadery C, Koshimori Y, Coakeley S, Harris M, Rusjan P, Kim J, Houle S, Strafella AP. Microglial activation in Parkinson’s disease using [18F]-FEPPA. J Neuroinflammation. 2017;14:8.
Reubi JC, Laissue J, Krenning E, Lamberts SWJ. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol. 1992;43:27–35.
Virgolini I, Pangerl T, Bischof C, Smith-Jones P, Peck-Radosavljevic M. Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer? Eur J Clin Investig. 1997;27:645–7.
Breeman WAP, de Blois E, Sze Chan H, Konijnenberg M, Kwekkeboom DJ, Krenning EP. 68Ga-labeled DOTA-peptides and 68Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med. 2011;41:314–21.
Schottelius M, Wester H-J. Molecular imaging targeting peptide receptors. Methods. 2009;48:161–77.
Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, Katzenellenbogen JA. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45–8.
Hostetler ED, Jonson SD, Welch MJ, Katzenellenbogen JA. Synthesis of 2-[18F]fluoroestradiol, a potential diagnostic imaging agent for breast cancer: strategies to achieve nucleophilic substitution of an electron-rich aromatic ring with [18F]F−. J Org Chem. 1999;64:178–85.
Kumar P, Mercer J, Doerkson C, Tonkin K, McEwan AJB. Clinical production, stability studies and PET imaging with 16-α-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients. J Pharm Pharm Sci. 2007;10:256s–65s.
Dehdashti F, Laforest R, Gao F, Aft RL, Dence CS, Zhou D, Shoghi KI, Siegel BA, Katzenellenbogen JA, Welch MJ. Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16α,17α-[(R)-(1′-α-furylmethylidene) dioxy]-19-norpregn-4-ene-3,20-dione. J Nucl Med. 2012;53:363–70.
Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91.
Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin avb3 expression in man. Clin Cancer Res. 2006;12:3942–9.
Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, Berganos R, Chang E, Liu SL, Shen B, Chin FT, Chen XY, Gambhir SS. Pilot pharmacokinetic and dosimetric studies of 18F-FPPRGD2: a PET radiopharmaceutical agent for imaging αvβ3 integrin levels. Radiology. 2011;260:182–91.
Mena E, Owenius R, Turkbey B, Sherry R, Bratslavsky G, Macholl S, Miller MP, Somer EJ, Lindenberg L, Adler S, Shih J, Choyke P, Kurdziel K. [18F]Fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ3 and αvβ5 integrins. Eur J Nucl Med Mol Imaging. 2014;41:1879–88.
Backer MV, Backer JM. Imaging key biomarkers of tumor angiogenesis. Theranostics. 2012;2:502–15.
Cai H, Conti PS. RGD-based PET tracers for imaging receptor integrin αvβ3 expression. J Label Compd Radiopharm. 2013;56:264–79.
Sun X, Li Y, Liu T, Li Z, Zhang X, Chen X. Peptide-based imaging agents for cancer detection. Adv Drug Deliv Rev. 2017;110-111:38–51.
Rylova SN, Barnucz E, Fani M, Braun F, Werner M, Lassmann S, Maecke HR, Weber WA. Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy? J Nucl Med. 2014;55:1878–84.
Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, Eisenberger M, Carducci M, Fan H, Dannals RF, Chen Y, Mease RC, Szabo Z, Pomper MG, Cho SY. PSMA-based [18F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol. 2016;18:411–9.
Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schafer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–88.
Zinnhardt B, Pigeon H, Thézé B, Viel T, Wachsmuth L, Fricke IB, Schelhaas S, Honold L, Schwegmann K, Wagner S, Faust A, Faber C, Kuhlmann MT, Hermann S, Schäfers M, Winkeler A, Jacobs AH. Combined PET imaging of the inflammatory tumor microenvironment identifies margins of unique radiotracer uptake. Cancer Res. 2017;77:1831–41.
Hughes AJ. Clinicopathological aspects of Parkinson’s disease. Eur Neurol. 1997;38:13–20.
Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES. Cerebral metabolism of 6-[18F]fluoro-l-3,4-dihydroxyphenylalanine in the primate. J Neurochem. 1987;48:1077–82.
DeJesus OT, Endres CJ, Shelton SE, Nickles RJ, Holden JE. Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: comparison with 6-fluorodopa. J Nucl Med. 1997;38:630–6.
Wong D, Wagner H, Tune L, Dannals R, Pearlson G, Links J, Tamminga C, Broussolle E, Ravert H, Wilson A, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science. 1986;234:1558–63.
Farde L, Ehrin E, Eriksson L, Greitz T, Hall H, Hedstrom CG, Litton JE, Sedvall G. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci U S A. 1985;82:3863–7.
Albrecht DS, Granziera C, Hooker JM, Loggia ML. In vivo imaging of human neuroinflammation. ACS Chem Neurosci. 2016;7:470–83.
Kersemans K, Van Laeken N, De Vos F. Radiochemistry devoted to the production of monoamine oxidase (MAO-A and MAO-B) ligands for brain imaging with positron emission tomography. J Label Compd Radiopharm. 2013;56:78–88.
Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 2005;6:112–7.
Verburg FA, Heinzel A, Hänscheid H, Mottaghy FM, Luster M, Giovanella L. Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine. Eur J Nucl Med Mol Imaging. 2014;41:199–201.
Vogenberg FR, Isaacson Barash C, Pursel M. Personalized medicine: part 1: evolution and development into theranostics. P T. 2010;35:560–76.
Funkhouser J. Reinventing pharma: the theranostic revolution. Curr Drug Discov. 2002;2002:17–9.
Jeelani S, Jagat Reddy R, Maheswaran T, Asokan G, Dany A, Anand B. Theranostics: a treasured tailor for tomorrow. J Pharm Bioallied Sci. 2014;6:6–8.
Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih M-C, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen C-T, Pu Y. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:27–38.
Velikyan I. Molecular imaging and radiotherapy: theranostics for personalized patient management. Theranostics. 2012;2:424–6.
Teng F-F, Meng X, Sun X-D, Yu J-M. New strategy for monitoring targeted therapy: molecular imaging. Int J Nanomedicine. 2013;8:3703–13.
Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008;77:311–9.
Jadvar H, Chen X, Cai W, Mahmood U. Radiotheranostics in cancer diagnosis and management. Radiology. 2018;286:388–400.
Fahey FH, Grant FD, Thrall JH. Saul Hertz, MD, and the birth of radionuclide therapy. EJNMMI Phys. 2017;4:15.
Hertz B. Dr. Saul Hertz (1905–1950) discovers the medical uses of radioactive iodine: the first targeted cancer therapy thyroid cancer – advances in diagnosis and therapy. London: IntechOpen; 2016.
Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc. 1946;132:838–47.
Volkert WA, Huffman TJ. Therapeutic radiopharmaceuticals. Chem Rev. 1999;99:2269–92.
Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJG, Tennvall J, Bombardieri E. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941.
Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev. 2004;24:357–97.
Zukotynski K, Jadvar H, Capala J, Fahey F. Targeted radionuclide therapy: practical applications and future prospects. Biomark Cancer. 2016;8:35–8.
Dash A, Pillai MRA, Knapp FF. Production of 177Lu for targeted radionuclide therapy: available options. Nucl Med Mol Imaging. 2015;49:85–107.
Fani M, Maecke HR, Okarvi SM. Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics. 2012;2:481–501.
Srinivasarao M, Galliford CV, Low PS. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov. 2015;14:203.
Ding H, Wu F. Image guided biodistribution and pharmacokinetic studies of theranostics. Theranostics. 2012;2:1040–53.
Santos-Oliveira R, Smith SW, Carneiro-Leão AMA. Radiopharmaceuticals drug interactions: a critical review. An Acad Bras Cienc. 2008;80:665–75.
Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJG, Tennvall J. Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”. Eur J Nucl Med Mol Imaging. 2007;34:772–86.
Banerjee SR, Pomper MG. Clinical applications of gallium-68. Appl Radiat Isot. 2013;76:2–13.
Das T, Banerjee S. Theranostic applications of lutetium-177 in radionuclide therapy. Curr Radiopharm. 2016;9:94–101.
Elgqvist J, Frost S, Pouget J-P, Albertsson P. The potential and hurdles of targeted alpha therapy – clinical trials and beyond. Front Oncol. 2013;3:324.
Goffredo V, Paradiso A, Ranieri G, Gadaleta CD. Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999–2009). Crit Rev Oncol Hematol. 2011;80:393–410.
Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev. 2008;60:1347–70.
Brechbiel MW. Bifunctional chelates for metal nuclides. Q J Nucl Med Mol Imaging. 2008;52:166–73.
Milenic DE, Baidoo KE, Kim Y-S, Barkley R, Brechbiel MW. Comparative studies on the therapeutic benefit of targeted [small alpha]-particle radiation therapy for the treatment of disseminated intraperitoneal disease. Dalton Trans. 2017;46:14591–601.
Pool SE, Krenning EP, Koning GA, van Eijck CHJ, Teunissen JJM, Kam B, Valkema R, Kwekkeboom DJ, de Jong M. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med. 2010;40:209–18.
Bison SM, Konijnenberg MW, Melis M, Pool SE, Bernsen MR, Teunissen JJM, Kwekkeboom DJ, de Jong M. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clin Transl Imaging. 2014;2:55–66.
Keskin O, Yalcin S. A review of the use of somatostatin analogs in oncology. OncoTargets Ther. 2013;6:471–83.
Heck MM, Schwaiger S, Knorr K, Retz M, Maurer T, Janssen F, D’Alessandria C, Wester H-J, Gschwend JE, Schwaiger M, Tauber R, Eiber M. Clinical experience with 100 consecutive patients treated with 177Lu-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer. J Clin Oncol. 2018;36:206.
Lütje S, Heskamp S, Cornelissen AS, Poeppel TD, van den Broek SAMW, Rosenbaum-Krumme S, Bockisch A, Gotthardt M, Rijpkema M, Boerman OC. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics. 2015;5:1388–401.
Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90.
Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T, Baum RP. Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results. J Nucl Med. 2017;58:75–80.
Stoykow C, Erbes T, Maecke HR, Bulla S, Bartholoma M, Mayer S, Drendel V, Bronsert P, Werner M, Gitsch G, Weber WA, Stickeler E, Meyer PT. Gastrin-releasing peptide receptor imaging in breast cancer using the receptor antagonist 68Ga-RM2 and PET. Theranostics. 2016;6:1641–50.
Kruljac I, Pape UF. “Neuroendocrine carcinomas” revisited – a 2017 update and future perspectives. Endocr Oncol Metab. 2017;3:37–42.
Klöppel G. Neuroendocrine neoplasms: dichotomy, origin and classifications. Visc Med. 2017;33:324–30.
Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Müller-Nordhorn J, Koch M, Röcken C, Rindi G, Ruszniewski P, Wiedenmann B, Pape U-F. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117:3332–41.
Klöppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2011;18:S1–S16.
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.
Reubi J, Waser B, Schaer J-C, Laissue JA. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836–46.
Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J Nucl Med. 2008;49:1735–8.
Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PPA, O’Carroll AM, Patel YC, Schonbrunn A, Taylor JE, Reisine T. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci. 1995;16:86–8.
Csaba Z, Peineau S, Dournaud P. Molecular mechanisms of somatostatin receptor trafficking. J Mol Endocrinol. 2012;48:R1–R12.
Nilsson O, Kölby L, Wängberg B, Wigander A, Billig H, William-Olsson L, Fjälling M, Forssell-Aronsson E, Ahlman H. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer. 1998;77:632–7.
Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179:77–9.
Burgus R, Ling N, Butcher M, Guillemin R. Primary structure of somatostatin, a hypothalamic peptide that inhibits the secretion of pituitary growth hormone. Proc Natl Acad Sci U S A. 1973;70:684–8.
Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev. 1995;16:427–42.
Panetta R, Greenwood MT, Warszynska A, Demchyshyn LL, Day R, Niznik HB, Srikant CB, Patel YC. Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. Mol Pharmacol. 1994;45:417–27.
Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–98.
Reubi JC, Schaer J-C, Laissue JA, Waser B. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism. 1996;45:39–41.
Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. J Nucl Med. 2011;52:42S–55S.
Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34:228–52.
Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389–427.
Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982–93.
Öberg K. Molecular imaging radiotherapy: theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics. 2012;2:448–58.
Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, Chiti A. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004–10.
Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54:364–72.
Kam BLR, Teunissen JJM, Krenning EP, de Herder WW, Khan S, van Vliet EI, Kwekkeboom DJ. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:103–12.
Marincek N, Jörg A-C, Brunner P, Schindler C, Koller MT, Rochlitz C, Müller-Brand J, Maecke HR, Briel M, Walter MA. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. J Transl Med. 2013;11:17.
Kratochwil C, Bruchertseifer F, Giesel F, Apostolidis C, Haberkorn U, Morgenstern A. Ac-225-DOTATOC – an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors. J Nucl Med. 2015;56:1232.
Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, Murphy K, Haberkorn U, Morgenstern A. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106–19.
Helisch A, Förster GJ, Reber H, Buchholz H-G, Arnold R, Göke B, Weber MM, Wiedenmann B, Pauwels S, Haus U, Bouterfa H, Bartenstein P. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1386–92.
Singh A, van der Meulen NP, Müller C, Klette I, Kulkarni HR, Türler A, Schibli R, Baum RP. First-in-human PET/CT imaging of metastatic neuroendocrine neoplasms with cyclotron-produced 44Sc-DOTATOC: a proof-of-concept study. Cancer Biother Radiopharm. 2017;32:124–32.
Baum RP, Kulkarni HR. THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy – the bad Berka experience. Theranostics. 2012;2:437–47.
Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Hörsch D, O’Dorisio MS, O’Dorisiol TM, Howe JR, Cremonesi M, Kwekkeboom DJ. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.
Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, Bartolomei M, Lombardo D, Ferrari ME, Sansovini M, Chinol M, Paganelli G. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35.
Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O’Dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46:62S–6S.
Strosberg JR, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O’Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.
Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, Lepensky C, Kwekkeboom DJ, Baum RP, Krenning EP, Modlin IM. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19.
Kwekkeboom DJ, Krenning EP. Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30:179–91.
Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, Mäcke HR, Rochlitz C, Müller-Brand J, Walter MA. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416–23.
Sabet A, Ezziddin K, Pape U-F, Reichman K, Haslerud T, Ahmadzadehfar H, Biersack H-J, Nagarajah J, Ezziddin S. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. Eur J Nucl Med Mol Imaging. 2014;41:505–10.
Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, Erchegyi J, Rivier J, Mäcke HR, Reubi JC. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006;103:16436–41.
Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, Fischer R, Rivier JEF, Reubi JC, Maecke HR, Weber WA. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248–52.
Fani M, Kolenc Peitl P, Velikyan I. Current status of radiopharmaceuticals for the theranostics of neuroendocrine neoplasms. Pharmaceuticals. 2017;10:30.
Ahmadzadehfar H. Targeted therapy for metastatic prostate cancer with radionuclides prostate cancer. London: IntechOpen; 2016.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin Donald M, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136:E359–86.
Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, Chen Y, Yang X, Cho SY, Nimmagadda S, Pomper MG. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging. 2015;59:241–68.
O’Keefe DS, Bacich DJ, Heston WDW. Prostate specific membrane antigen. In: Chung L, Issacs W, Simons J, editors. Prostate cancer, biology, genetics, and the new therapeutics. Totowa, NJ: Humana; 2001. p. 307–26.
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.
Dumas F, Gala Jean L, Berteau P, Brasseur F, Eschwège P, Paradis V, Lacour B, Philippe M, Loric S. Molecular expression of PSMA mRNA and protein in primary renal tumors. Int J Cancer. 1999;80:799–803.
Gala J-L, Loric S, Guiot Y, Denmeade SR, Gady A, Brasseur F, Heusterspreute M, Eschwège P, De Nayer P, Van Cangh P, Tombal B. Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? Clin Cancer Res. 2000;6:4049–54.
Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–8.
Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Mühlmann G, Öfner D, Zelger B, Ensinger C, Yang XJ, Geley S, Margreiter R, Bander NH. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol. 2009;40:1754–61.
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res. 1983;43:1809–18.
Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927–35.
Ellis RJ, Kaminsky DA, Zhou EH, Fu P, Chen W-D, Brelin A, Faulhaber PF, Bodner D. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (prostascint) in a cohort diagnosed with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011;81:29–34.
Sodee DB, Malguria N, Faulhaber P, Resnick MI, Albert J, Bakale G. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer11A complete list of the ProstaScint imaging centers is provided in the appendix. Urology. 2000;56:988–93.
Taneja SS. ProstaScint® scan: contemporary use in clinical practice. Rev Urol. 2004;6:S19–28.
Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, Haberkorn U, Kopka K, Eder M. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20.
Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG. 2-(3-(1-Carboxy-5-(6-[18F]fluoro-pyridine-3-carbonyl)-amino-pentyl)-U reido)-pentanedioic acid, [18F] DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645–53.
Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, Endres CJ, Dannals RF, Sgouros G, Lodge M, Eisenberger MA, Rodriguez R, Carducci MA, Rojas C, Slusher BS, Kozikowski AP, Pomper MG. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883–91.
Eder M, Schäfer M, Bauder-Wüst U, Hull W-E, Wängler C, Mier W, Haberkorn U, Eisenhut M. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97.
Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69:6932–40.
Maresca KP, Hillier SM, Femia FJ, Keith D, Barone C, Joyal JL, Zimmerman CN, Kozikowski AP, Barrett JA, Eckelman WC, Babich JW. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009;52:347–57.
Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC, Vranesic M, Bhatnagar A, Sgouros G, Cho SY, Pomper MG. Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565–74.
Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Klette I, Eiber M, Schwaiger M, Wester H-J. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76.
Langton-Webster B, Berkman C, Slater J, Jivan S, Neumann K, Whalley E, Ketteridge P, Behr S, Aggarwal R, VanBrocklin H. Development of a novel PSMA-targeted PET imaging agent, CTT1057, for use in prostate cancer. J Nucl Med. 2016;57:467.
Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591–601.
Kampmeier F, Williams JD, Maher J, Mullen GE, Blower PJ. Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA). EJNMMI Res. 2014;4:13.
Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22:2522–31.
Olafsen T, Bartlett D, Ho D, Zhang G, Torgov M, Keppler J, Behrenbruch C, Wu A, Pandit-Taskar N, Morris MJ, Lewis JS, Lyashchenko SK, Gudas JMJ. Minibody imaging of prostate-specific membrane antigen (PSMA): from concept to clinic. Clin Oncol. 2014;32:e16057.
Flores O, Santra S, Kaittanis C, Bassiouni R, Khaled AS, Khaled AR, Grimm J, Perez JM. PSMA-targeted theranostic nanocarrier for prostate cancer. Theranostics. 2017;7:2477–94.
Kopka K, Benešová M, Bařinka C, Haberkorn U, Babich J. Glu-Ureido-based inhibitors of prostate-specific membrane antigen: lessons learned during the development of a novel class of low-molecular-weight theranostic radiotracers. J Nucl Med. 2017;58:17S–26S.
von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2018;45:496–508.
Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U. Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280–92.
Coleman RE, Barrett JA, Hussain A, Slawin KM, Armor T, LaFrance ND, Babich JW. Prostate-specific membrane antigen (PSMA)-targeted imaging of metastatic prostate cancer (PCa) via small molecule inhibitors: comparison to bone scan, CT/MRI, and 111In capromab. J Clin Oncol. 2011;29:4658.
Schmidkonz C, Cordes M, Beck M, Goetz TI, Schmidt D, Prante O, Bäuerle T, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P. SPECT/CT with the PSMA ligand 99mTc-MIP-1404 for whole-body primary staging of patients with prostate cancer. Clin Nucl Med. 2018;43:225–31.
Afshar-Oromieh A, Haberkorn U, Hadaschik B, Habl G, Eder M, Eisenhut M, Schlemmer HP, Roethke MC. PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:1629–30.
Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, Guner G, Munari E, Partin AW, Pavlovich CP, Han M, Carter HB, Bivalacqua TJ, Blackford A, Holt D, Dannals RF, Netto GJ, Lodge MA, Mease RC, Pomper MG, Cho SY. 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med. 2015;56:1003–10.
Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benešová M, Eder M, Neels OC, Eisenhut M, Kübler W, Holland-Letz T, Giesel FL, Mier W, Kopka K, Haberkorn U. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705.
Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA, Cho S, Armor T, Stubbs JB, Maresca KP, Stabin MG, Joyal JL, Eckelman WC, Babich JW. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013;54:380–7.
Meyrick DP, Asokendaran M, Skelly LA, Lenzo NP, Henderson A. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer. Nucl Med Commun. 2017;38:956–63.
Schottelius M, Wirtz M, Eiber M, Maurer T, Wester H-J. [111In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Res. 2015;5:68.
Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann C. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085–6.
Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.
Schuhmacher J, Matys R, Hauser H, Maier-Borst W, Matzku S. Labeling of monoclonal antibodies with a 67Ga-phenolic aminocarboxylic acid chelate. Eur J Nucl Med. 1986;12:397–404.
Zöller M, Schuhmacher J, Reed J, Maier-Borst W, Matzku S. Establishment and characterization of monoclonal antibodies against an octahedral gallium chelate suitable for immunoscintigraphy with PET. J Nucl Med. 1992;33:1366–72.
Dam JH, Olsen BB, Baun C, Høilund-Carlsen PF, Thisgaard H. A PSMA ligand labeled with cobalt-55 for PET imaging of prostate cancer. Mol Imaging Biol. 2017;19:915–22.
Han X-D, Liu C, Liu F, Xie Q-H, Liu T-L, Guo X-Y, Xu X-X, Yang X, Zhu H, Yang Z. 64Cu-PSMA-617: a novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model. Oncotarget. 2017;8:74159–69.
Umbricht CA, Benešová M, Schmid RM, Türler A, Schibli R, van der Meulen NP, Müller C. 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617. EJNMMI Res. 2017;7:9.
Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, Tritschler S, Stief CG, Kopka K, Haberkorn U, Bartenstein P, Böning G. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42–51.
Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–4.
Sathekge M, Knoesen O, Meckel M, Modiselle M, Vorster M, Marx S. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1099–100.
Bräuer A, Grubert LS, Roll W, Schrader AJ, Schäfers M, Bögemann M, Rahbar K. 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1663–70.
von Eyben FE, Kiljunen T, Joensuu T, Kairemo K, Uprimny C, Virgolini I. 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer. Oncotarget. 2017;8:66112–6.
Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, Bal C. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging. 2017;44:81–91.
Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Wei X, Schlenkhoff C, Hauser S, Essler M. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017;44:1448–54.
Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, Essler M, Ahmadzadehfar H. The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1473–9.
Kratochwil C, Bruchertseifer F, Giesel FL, Apostolidis C, Haberkorn U, Morgenstern A. Ac-225-PSMA-617 for PSMA targeting alpha-radiation therapy of 28 patients with mCRPC. Eur J Nucl Med Mol Imaging. 2016;43:S137.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33.
Giesel FL, Kesch C, Yun M, Cardinale J, Haberkorn U, Kopka K, Kratochwil C, Hadaschik BA. 18F-PSMA-1007 PET/CT detects micrometastases in a patient with biochemically recurrent prostate cancer. Clin Genitourin Cancer. 2017;15:e497–9.
Lee CM, Tannock IF. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer. 2010;10:255.
Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm. 2009;24:155–61.
Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693–713.
Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24:1720–40.
Troyer JK, Beckett ML, Wright GL. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate. 1997;30:232–42.
Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003;170:1717–21.
DiPippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. Prostate. 2015;75:303–13.
Fleuren EDG, Versleijen-Jonkers YMH, Heskamp S, van Herpen CML, Oyen WJG, van der Graaf WTA, Boerman Otto C. Theranostic applications of antibodies in oncology. Mol Oncol. 2014;8:799–812.
Olson WC, Israel RJ. Antibody-drug conjugates targeting prostate-specific membrane antigen. Front Biosci. 2014;19:12–33.
Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, Chalasani S, Weber WA, Spratt DE, Veach DR, Bander NH, Larson SM, Zanzonico PB, Osborne JR. Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. EJNMMI Res. 2016;6:7.
Pandit-Taskar N, O’Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM. Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:2093–105.
Pandit-Taskar N, O’Donoghue JA, Divgi CR, Wills EA, Schwartz L, Gönen M, Smith-Jones P, Bander NH, Scher HI, Larson SM, Morris MJ. Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015;5:28.
Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182–91.
Dumont RA, Tamma M, Braun F, Borkowski S, Reubi JC, Maecke H, Weber WA, Mansi R. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. J Nucl Med. 2013;54:762–9.
Sancho V, Florio AD, Moody TW, Jensen RT. Bombesin receptor-mediated imaging and cytotoxicity. Rev Curr Stat Curr Drug Deliv. 2011;8:79–134.
Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, Reubi JC. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49:318–26.
Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, Maecke HR, Reubi JC, Weber WA. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist – from mice to men. Theranostics. 2014;4:412–9.
Bodei L, Ferrari M, Nunn A, Llull J, Cremonesi M, Martano L, Laurora G, Scardino E, Tiberini S, Bufi G, Eaton S, de Cobelli O, Paganelli G. 177Lu-AMBA bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations. Eur J Nucl Med Mol Imaging. 2007;34:S221.
Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, Vasanawala S, Gambhir SS, Iagaru A. Pilot comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in patients with biochemically recurrent prostate cancer. J Nucl Med. 2016;57:557–62.
Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390:298–310.
Kosmas C, Stamatopoulos K, Stavroyianni N, Tsavaris N, Papadaki T. Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia. 2002;16:2004.
Dotan E, Aggarwal C, Smith MR. Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin’s lymphoma. P T. 2010;35:148–57.
Goldsmith SJ. Radioimmunotherapy of lymphoma: bexxar and zevalin. Semin Nucl Med. 2010;40:122–35.
Boucek JA, Turner JH. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2005;32:458–69.
Dietlein M, Pels H, Schulz H, Staak O, Borchmann P, Schomäcker K, Fischer T, Eschner W, Strandmann Elke P, Schicha H, Engert A, Schnell R. Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol. 2005;74:348–52.
Leahy MF, Seymour JF, Hicks RJ, Turner JH. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24:4418–25.
Rizzieri D. Zevalin® (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned? Crit Rev Oncol Hematol. 2016;105:5–17.
Spies SM. Imaging and dosing in radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med. 2004;34:10–3.
Evens AM, Gordon LI. Radioimmunotherapy in non-Hodgkin’s lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond. Clin Lymphoma. 2004;5:S11–5.
Scholz CW, Pinto A, Linkesch W, Lindén O, Viardot A, Keller U, Hess G, Lastoria S, Lerch K, Frigeri F, Arcamone M, Stroux A, Frericks B, Pott C, Pezzutto A. 90Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol. 2013;31:308–13.
Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–63.
Iagaru A, Mittra ES, Ganjoo K, Knox SJ, Goris ML. 131I-tositumomab (Bexxar®) vs. 90Y-ibritumomab (Zevalin®) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma. Mol Imaging Biol. 2010;12:198–203.
DeNardo GL, Kukis DL, Shen S, DeNardo DA, Meares CF, DeNardo SJ. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin’s lymphoma. Clin Cancer Res. 1999;5:533–41.
O’Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Carr CE, Mirick GR, DeNardo SJ. A clinical trial of radioimmunotherapy with 67Cu-21T-BAT-Lym-1 for non-Hodgkin’s lymphoma. J Nucl Med. 1999;40:2014–20.
Peled A, Tavor S. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics. 2013;3:34–9.
Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet. 2015;385:2197–208.
Gourni E, Demmer O, Schottelius M, D’Alessandria C, Schulz S, Dijkgraaf I, Schumacher U, Schwaiger M, Kessler H, Wester H-J. PET of CXCR4 expression by a 68Ga-labeled highly specific targeted contrast agent. J Nucl Med. 2011;52:1803–10.
Lapa C, Schreder M, Schirbel A, Samnick S, Kortüm KM, Herrmann K, Kropf S, Einsele H, Buck AK, Wester H-J, Knop S, Lückerath K. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma – comparison to [18F]FDG and laboratory values. Theranostics. 2017;7:205–12.
Vag T, Gerngross C, Herhaus P, Eiber M, Philipp-Abbrederis K, Graner F-P, Ettl J, Keller U, Wester H-J, Schwaiger M. First experience with chemokine receptor CXCR4-targeted PET imaging of patients with solid cancers. J Nucl Med. 2016;57:741–6.
Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Hänscheid H, Lückerath K, Schreder M, Bluemel C, Knott M, Keller U, Schirbel A, Samnick S, Lassmann M, Kropf S, Buck AK, Einsele H, Wester H-J, Knop S. First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease. J Nucl Med. 2016;57:248–51.
Lapa C, Herrmann K, Schirbel A, Hänscheid H, Lückerath K, Schottelius M, Kircher M, Werner RA, Schreder M, Samnick S, Kropf S, Knop S, Buck AK, Einsele H, Wester H-J, Kortüm KM. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma. Theranostics. 2017;7:1589–97.
Lau J, Lin KS, Benard F. Past, present, and future: development of theranostic agents targeting carbonic anhydrase IX. Theranostics. 2017;7:4322–39.
Harris AL. Hypoxia – a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38.
Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7:168.
Divgi CR, Uzzo RG, Gatsonis C, Bartz R, Treutner S, Yu JQ, Chen D, Carrasquillo JA, Larson S, Bevan P, Russo P. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol. 2013;31:187–94.
Muselaers CHJ, Boerman OC, Oosterwijk E, Langenhuijsen JF, Oyen WJG, Mulders PFA. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol. 2013;63:1101–6.
Stillebroer AB, Boerman OC, Desar IME, Boers-Sonderen MJ, van Herpen CML, Langenhuijsen JF, Smith-Jones PM, Oosterwijk E, Oyen WJG, Mulders PFA. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2013;64:478–85.
Askoxylakis V, Garcia-Boy R, Rana S, Krämer S, Hebling U, Mier W, Altmann A, Markert A, Debus J, Haberkorn U. A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology. PLoS One. 2011;5:e15962.
Rami M, Cecchi A, Montero J-L, Innocenti A, Vullo D, Scozzafava A, Winum J-Y, Supuran Claudiu T. Carbonic anhydrase inhibitors: design of membrane-impermeant copper(II) complexes of DTPA-, DOTA-, and TETA-tailed sulfonamides targeting the tumor-associated transmembrane isoform IX. ChemMedChem. 2008;3:1780–8.
Davidoff AM. Neuroblastoma. Semin Pediatr Surg. 2012;21:2–14.
Pashankar FD, O’Dorisio MS, Menda Y. MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use. J Nucl Med. 2005;46:55S–61S.
DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol. 2008;35:S35–48.
El-Maghraby T. 131I-MIBG in the diagnosis of primary and metastatic neuroblastoma. Gulf J Oncolog. 2007;2007:33–41.
Kraal KCJM, Bleeker GM, van Eck-Smit BLF, van Eijkelenburg NKA, Berthold F, van Noesel MM, Caron HN, Tytgat GAM. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients. Eur J Cancer. 2017;76:188–96.
Streby KA, Shah N, Ranalli MA, Kunkler A, Cripe TP. Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy. Pediatr Blood Cancer. 2015;62:5–11.
Luo Y, Pan Q, Yao S, Yu M, Wu W, Xue H, Kiesewetter DO, Zhu Z, Li F, Zhao Y, Chen X. Glucagon-like peptide-1 receptor PET/CT with 68Ga-NOTA-exendin-4 for detecting localized insulinoma: a prospective cohort study. J Nucl Med. 2016;57:715–20.
Velikyan I, Bulenga TN, Selvaraju R, Lubberink M, Espes D, Rosenström U, Eriksson O. Dosimetry of [177Lu]-DO3A-VS-Cys40-Exendin-4 – impact on the feasibility of insulinoma internal radiotherapy. Am J Nucl Med Mol Imaging. 2015;5:109–26.
Roosenburg S, Laverman P, van Delft FL, Boerman OC. Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors. Amino Acids. 2011;41:1049–58.
Rottenburger C, Nicolas G, McDougall L, Kaul F, Cachovan M, Schibli R, Geistlich S, Béhé M, Wild D, Christ E. Evaluation of the CCK-2-receptor agonist 177Lu-PP-F11N for peptide receptor radionuclide therapy (PRRT) of medullary thyroid carcinoma – first results of a phase 0 ‘Lumed’ study. Endocr Abstr. 2018;56:GP234.
Cachin F, Miot-Noirault E, Gillet B, Isnardi V, Labeille B, Payoux P, Meyer N, Cammilleri S, Gaudy C, Razzouk-Cadet M, Lacour JP, Granel-Brocard F, Tychyj C, Benbouzid F, Grange JD, Baulieu F, Kelly A, Merlin C, Mestas D, Gachon F, Chezal JM, Degoul F, D’Incan M. 123I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial. J Nucl Med. 2014;55:15–22.
Mier W, Kratochwil C, Hassel JC, Giesel FL, Beijer B, Babich JW, Friebe M, Eisenhut M, Enk A, Haberkorn U. Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52. J Nucl Med. 2014;55:9–14.
Sahlmann Carsten O, Homayounfar K, Niessner M, Dyczkowski J, Conradi L-C, Braulke F, Meller B, Beißbarth T, Ghadimi BM, Meller J, Goldenberg David M, Liersch T. Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: safety, feasibility, and long-term efficacy results of a prospective phase 2 study. Cancer. 2016;123:638–49.
Sultana A, Shore S, Raraty MGT, Vinjamuri S, Evans JE, Smith CT, Lane S, Chauhan S, Bosonnet L, Garvey C, Sutton R, Neoptolemos JP, Ghaneh P. Randomised phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen (131I)KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer. 2009;9:66.
Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Knoedler P, Lang K, Buck AK, Reiners C, Allolio B, Schirbel A. [131I]Iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J Clin Endocrinol Metabol. 2012;97:914–22.
Kreissl MC, Schirbel A, Fassnacht M, Haenscheid H, Verburg FA, Bock S, Saeger W, Knoedler P, Reiners C, Buck AK, Allolio B, Hahner S. [123I]Iodometomidate imaging in adrenocortical carcinoma. J Clin Endocrinol Metabol. 2013;98:2755–64.
Bergmann R, Meckel M, Kubíček V, Pietzsch J, Steinbach J, Hermann P, Rösch F. 177Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment. EJNMMI Res. 2016;6:5.
Fellner M, Baum RP, Kubíček V, Hermann P, Lukeš I, Prasad V, Rösch F. PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: first human study. Eur J Nucl Med Mol Imaging. 2010;37:834.
Artiko V, Afgan A, Petrović J, Radović B, Petrović N, Vlajković M, Šobic-Šaranović D, Obradović V. Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC. Nucl Med Rev. 2016;19:99–103.
Hankus J, Tomaszewska R. Neuroendocrine neoplasms and somatostatin receptor subtypes expression. Nucl Med Rev. 2016;19:111–7.
Trogrlic M, Tezak S. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors. Nucl Med Rev. 2016;19:74–80.
King RC, Surfraz MB-U, Biagini SCG, Blower PJ, Mather SJ. How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies. Cambridge: Dalton Transactions; 2007. p. 4998–5007.
Meszaros LK, Dose A, Biagini SCG, Blower PJ. Hydrazinonicotinic acid (HYNIC) – coordination chemistry and applications in radiopharmaceutical chemistry. Inorg Chim Acta. 2010;363:1059–69.
Decristoforo C, Mather SJ. Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide. Bioconjug Chem. 1999;10:431–8.
Storch D, Béhé M, Walter MA, Chen J, Powell P, Mikolajczak R, Mäcke HR. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med. 2005;46:1561–9.
Maina T, Nock B, Nikolopoulou A, Sotiriou P, Loudos G, Maintas D, Cordopatis P, Chiotellis E. [99mTc]demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging. 2002;29:742–53.
Maina T, Nock BA, Cordopatis P, Bernard BF, Breeman WAP, van Gameren A, van den Berg R, Reubi J-C, Krenning EP, de Jong M. [99mTc]Demotate 2 in the detection of sst2-positive tumours: a preclinical comparison with [111In]DOTA-tate. Eur J Nucl Med Mol Imaging. 2006;33:831–40.
Wild D, Fani M, Behe M, Brink I, Rivier JEF, Reubi JC, Maecke HR, Weber WA. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med. 2011;52:1412–7.
Morgat C, Mishra AK, Varshney R, Allard M, Fernandez P, Hindié E. Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors. J Nucl Med. 2014;55:1650–7.
Maxwell JE, Howe JR. Imaging in neuroendocrine tumors: an update for the clinician. Int J Endocr Oncol. 2015;2:159–68.
Savelli G, Bertagna F, Franco F, Dognini L, Bosio G, Migliorati E, Rodella C, Biasiotto G, Bettinsoli G, Minari C, Zaniboni A, Ferrari C, Tomassetti P, Ferrari V, Giubbini R. Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide. Cancer. 2012;118:2915–24.
Cwikla JB, Sankowski A, Seklecka N, Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG, Mikolajczak R, Pawlak D, Stepien K, Walecki J. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol. 2010;21:787–94.
Sergieva S, Robev B, Dimcheva M, Fakirova A, Hristoskova R. Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs). Nucl Med Rev. 2016;19(2):81–7.
Decristoforo C, Maina T, Nock B, Gabriel M, Cordopatis P, Moncayo R. 99mTc-Demotate 1: first data in tumour patients—results of a pilot/phase I study. Eur J Nucl Med Mol Imaging. 2003;30:1211–9.
Reubi JC, Schaer J-C, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997;57:1377–86.
Reubi JC. Targeting CCK receptors in human cancers. Curr Top Med Chem. 2007;7:1239–42.
Behr TM, Béhé MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med. 2002;32:97–109.
Gotthardt M, Béhé MP, Grass J, Bauhofer A, Rinke A, Schipper ML, Kalinowski M, Arnold R, Oyen WJG, Behr TM. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer. 2006;13:1203–11.
Gotthardt M, Béhé P, Beuter D, Battmann A, Bauhofer A, Schurrat T, Schipper M, Pollum H, Oyen WJG, Behr TM. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2006;33:1273–9.
Kosowicz J, Mikołajczak R, Czepczyński R, Ziemnicka K, Gryczyńska M, Sowiński J. Two peptide receptor ligands 99mTc-EDDA/HYNIC-Tyr3-octreotide and 99mTc-EDDA/HYNIC-DGlu-octagastrin for scintigraphy of medullary thyroid carcinoma. Cancer Biother Radiopharm. 2007;22:613–28.
Breeman WAP, Fröberg AC, de Blois E, van Gameren A, Melis M, de Jong M, Maina T, Nock BA, Erion JL, Mäcke HR, Krenning EP. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. Nucl Med Biol. 2008;35:839–49.
Reubi JC, Maecke HR. Approaches to multireceptor targeting: hybrid radioligands, radioligand cocktails, and sequential radioligand applications. J Nucl Med. 2017;58:10S–6S.
Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48:736–43.
Wild D, Béhé M, Wicki A, Storch D, Waser B, Gotthardt M, Keil B, Christofori G, Reubi JC, Mäcke HR. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med. 2006;47:2025–33.
Wild D, Mäcke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med. 2008;359:766–8.
Christ E, Wild D, Ederer S, Béhé M, Nicolas G, Caplin ME, Brändle M, Clerici T, Fischli S, Stettler C, Ell PJ, Seufert J, Gloor B, Perren A, Reubi JC, Forrer F. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. The Lancet Diabetes & Endocrinology. 2013;1:115–22.
Christ E, Wild D, Forrer F, Brändle M, Sahli R, Clerici T, Gloor B, Martius F, Maecke H, Reubi JC. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metabol. 2009;94:4398–405.
Sowa-Staszczak A, Trofimiuk-Müldner M, Stefańska A, Tomaszuk M, Buziak-Bereza M, Gilis-Januszewska A, Jabrocka-Hybel A, Głowa B, Małecki M, Bednarczuk T, Kamiński G, Kowalska A, Mikołajczak R, Janota B, Hubalewska-Dydejczyk A. 99mTc labeled glucagon-like peptide-1-analogue (99mTc-GLP1) scintigraphy in the management of patients with occult insulinoma. PLoS One. 2016;11:e0160714.
Sowa-Staszczak A, Pach D, Mikołajczak R, Mäcke H, Jabrocka-Hybel A, Stefańska A, Tomaszuk M, Janota B, Gilis-Januszewska A, Małecki M, Kamiński G, Kowalska A, Kulig J, Matyja A, Osuch C, Hubalewska-Dydejczyk A. Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging. 2013;40:524–31.
Buchegger F, Bonvin F, Kosinski M, Schaffland AO, Prior J, Reubi JC, Bläuenstein P, Tourwé D, García Garayoa E, Bischof Delaloye A. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med. 2003;44:1649–54.
Gabriel M, Decristoforo C, Woll E, Eisterer W, Nock B, Maina T, Moncayo R, Virgolini I. [99mTc]Demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study. Cancer Biother Radiopharm. 2011;26:557–63.
De Vincentis G, Scopinaro F, Varvarigou A, Ussof W, Schillaci O, Archimandritis S, Corleto V, Longo F, Fave GD. Phase I trial of technetium [Leu13] bombesin as cancer seeking agent: possible scintigraphic guide for surgery? Tumori. 2002;88:S28–30.
Soluri A, Scopinaro F, De Vincentis G, Varvarigou A, Scafé R, Massa R, Schillaci O, Spanu A, David V. 99mTc [13LEU] bombesin and a new gamma camera, the imaging probe, are able to guide mammotome breast biopsy. Anticancer Res. 2003;23:2139–42.
De Vincentis G, Remediani S, Varvarigou AD, Di Santo G, Iori F, Laurenti C, Scopinaro F. Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancer. Cancer Biother Radiopharm. 2004;19:81–4.
Scopinaro F, Varvarigou AD, Ussof W, De Vincentis G, Sourlingas TG, Evangelatos GP, Datsteris J, Archimandritis SC. Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. Cancer Biother Radiopharm. 2002;17:327–35.
Scopinaro F, De Vincentis G, Varvarigou AD, Laurenti C, Iori F, Remediani S, Chiarini S, Stella S. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging. 2003;30:1378–82.
Scopinaro F, De Vincentis G, Corazziari E, Massa R, Osti M, Pallotta N, Covotta A, Remediani S, Di Paolo M, Monteleone F, Varvarigou A. Detection of colon cancer with 99mTc-labeled bombesin derivative (99mTc-leu13-BN1). Cancer Biother Radiopharm. 2004;19:245–52.
Shariati F, Aryana K, Fattahi A, Forghani MN, Azarian A, Zakavi SR, Sadeghi R, Ayati N, Sadri K. Diagnostic value of 99mTc-bombesin scintigraphy for differentiation of malignant from benign breast lesions. Nucl Med Commun. 2014;35:620–5.
Santos-Cuevas CL, Ferro-Flores G, de Murphy CA, Pichardo-Romero PA. Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-Lys3-bombesin: biokinetics and dosimetry in women. Nucl Med Commun. 2008;29:741–7.
Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, Peers S, Thornback J, Slegers G, Dierckx RA. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med. 2000;27:1694–9.
Van de Wiele CV, Dumont F, Dierckx RA, Peers SH, Thornback JR, Slegers G, Thierens H. Biodistribution and dosimetry of 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med. 2001;42:1722–7.
Van de Wiele C, Phonteyne P, Pauwels P, Goethals I, Van den Broecke R, Cocquyt V, Dierckx RA. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J Nucl Med. 2008;49:260–4.
Ananias HJK, Yu Z, Dierckx RA, van der Wiele C, Helfrich W, Wang F, Yan Y, Chen X, de Jong IJ, Elsinga PH. Technetium-HYNIC(tricine/TPPTS)-Aca-bombesin(7–14) as a targeted imaging agent with MicroSPECT in a PC-3 prostate cancer xenograft model. Mol Pharm. 2011;8:1165–73.
Mather SJ, Nock BA, Maina T, Gibson V, Ellison D, Murray I, Sobnack R, Colebrook S, Wan S, Halberrt G, Szysko T, Powles T, Avril N. GRP receptor imaging of prostate cancer using [99mTc]Demobesin 4: a First-in-Man Study. Mol Imaging Biol. 2014;16:888–95.
Scopinaro F, De Vincentis G, Varvarigou AD. Use of radiolabeled bombesin in humans. J Clin Oncol. 2005;23:3170–1.
Varvarigou A, Bouziotis P, Zikos C, Scopinaro F, De Vincentis G. Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biother Radiopharm. 2004;19:219–29.
Nock BA, Nikolopoulou A, Galanis A, Cordopatis P, Waser B, Reubi J-C, Maina T. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005;48:100–10.
Abiraj K, Mansi R, Tamma M-L, Fani M, Forrer F, Nicolas G, Cescato R, Reubi JC, Maecke HR. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor–positive tumors. J Nucl Med. 2011;52:1970–8.
Maddalena ME, Fox J, Chen J, Feng W, Cagnolini A, Linder KE, Tweedle MF, Nunn AD, Lantry LE. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med. 2009;50:2017–24.
Thomas R, Chen J, Roudier MM, Vessella RL, Lantry LE, Nunn AD. In vitro binding evaluation of 177Lu-AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues. Clin Exp Metastasis. 2009;26:105–19.
Eder M, Schäfer M, Bauder-Wüst U, Haberkorn U, Eisenhut M, Kopka K. Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate. 2014;74:659–68.
Liolios C, Schäfer M, Haberkorn U, Eder M, Kopka K. Novel bispecific PSMA/GRPr targeting radioligands with optimized pharmacokinetics for improved PET imaging of prostate cancer. Bioconjug Chem. 2016;27:737–51.
Yao CH, Lin KJ, Weng CC, Hsiao IT, Ting YS, Yen TC, Jan TR, Skovronsky D, Kung MP, Wey SP. GMP-compliant automated synthesis of [18F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain. Appl Radiat Isot. 2010;68:2293–7.
Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci. 2005;102:5981–6.
Bařinka C, Rojas C, Slusher B, Pomper M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem. 2012;19:856–70.
Kozikowski AP, Nan F, Conti P, Zhang J, Ramadan E, Bzdega T, Wroblewska B, Neale JH, Pshenichkin S, Wroblewski JT. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem. 2001;44:298–301.
Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov. 2005;4:1015–26.
Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP, Pomper MG. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005;11:4022–8.
Hillier SM, Kern AM, Maresca KP, Marquis JC, Eckelman WC, Joyal JL, Babich JW. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med. 2011;52:1087–93.
Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, Solnes L, Maresca KP, Armor T, Joyal JL, Crummet R, Stubbs JB, Goldsmith SJ. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med. 2014;55:1791–8.
Bartholomä M, Valliant J, Maresca KP, Babich J, Zubieta J. Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals. Chem Commun. 2009;5:493–512.
Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013;54:1369–76.
Kimura H, Okuda H, Ishiguro M, Arimitsu K, Makino A, Nishii R, Miyazaki A, Yagi Y, Watanabe H, Kawasaki I, Ono M, Saji H. 18F-labeled pyrido[3,4-d]pyrimidine as an effective probe for imaging of L858R mutant epidermal growth factor receptor. ACS Med Chem Lett. 2017;8:418–22.
Lu G, Maresca KP, Hillier SM, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW. Synthesis and SAR of 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. Bioorg Med Chem Lett. 2013;23:1557–63.
Misra P, Humblet V, Pannier N, Maison W, Frangioni JV. Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy. J Nucl Med. 2007;48:1379–89.
Maresca KP, Hillier SM, Lu G, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW. Small molecule inhibitors of PSMA incorporating technetium-99m for imaging prostate cancer: effects of chelate design on pharmacokinetics. Inorg Chim Acta. 2012;389:168–75.
Goffin KE, Joniau S, Tenke P, Slawin K, Klein EA, Stambler N, Strack T, Babich J, Armor T, Wong V. Phase 2 study of 99mTc-trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic LN dissection. J Nucl Med. 2017;58:1408–13.
Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester H-J. Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med. 2017;58:235–42.
Weineisen M, Šimeček J, Schottelius M, Schwaiger M, Wester H-J. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014;4:63.
Reinfelder J, Kuwert T, Beck M, Sanders JC, Ritt P, Schmidkonz C, Hennig P, Prante O, Uder M, Wullich B, Goebell P. First experience with SPECT/CT using a 99mTc-labeled inhibitor for prostate-specific membrane antigen in patients with biochemical recurrence of prostate cancer. Clin Nucl Med. 2017;42:26–33.
Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon J, Heaney AP, Kunz PL, O’Dorisio TM, Salem R, Segelov E, Howe J, Pommier R, Brendtro K, Bashir M, Singh S, Soulen MC, Tang L, Zacks JS, Yao J, Bergsland E. The North American Neuroendocrine Society (NANETS) consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas. 2017;46:707–14.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ermert, J. et al. (2020). Radiopharmaceutical Sciences. In: Ahmadzadehfar, H., Biersack, HJ., Freeman, L., Zuckier, L. (eds) Clinical Nuclear Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-39457-8_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-39457-8_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-39455-4
Online ISBN: 978-3-030-39457-8
eBook Packages: MedicineMedicine (R0)